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In this thesis I examined the function of Fibroblast Growth Factor (FGF)
signaling in epicardial cells. Epicardial cells serve as the outer layer of the heart and
as a signaling center for the growing myocardium. In addition, during development,
epicardial cells differentiate into vascular smooth muscle cells (vsmc) and interstitial
fibroblasts. Epicardial cells undergo an epicardial to mesenchymal transition (EMT)
to give rise to these various cell types, which are termed epicardial derived cells
(EPDCs). Epicardial-derived vsmc are an essential component of the arterial network
in the myocardium, and the interstitial fibroblasts become part of the fibrous skeleton
of the myocardium. To populate the myocardium, EPDCs must migrate through the
subepicardial space and into the compact myocardium. Very little is known about
how this migration is initiated, maintained and guided.
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Although, FGF7 and FGF10 are expressed in the myocardium their function
was not known. Biochemically, these FGFs activate the b splice variants of FGFR1
and FGFR2. Here, I show that FGF10 siganls to the epicardium in vivo to induce
migration of EPDCs. Furthermore, I found that FGF10 promotes migration of EPDCs
that are fated to become interstitial fibroblasts. Embryonic cardiac fibroblasts are
important during late heart gestation because they induce proliferation of cardiac
myocytes. In hearts in which the FGF10/FGFR2b signaling pathway is disrupted,
cardiac fibroblasts fail to migrate into the myocardium. I posit that fewer interstitia l
cardiac fibroblasts results in decreased cardiac myocyte proliferation and a smaller
heart. Other growth factors like PDGFβ had been identified to activate migration of
epicardial-derived vsmc but not cardiac fibroblast. Thus it appears that specific
extracellular signaling pathways are required to control the migration of EPDClineages into the myocardium. These findings are an important contribution to the
understanding of epicardial development. Epicardial and EPDC are not only
important for heart development, but are thought to be essential for heart repair and
regeneration due to the potential of these cells to differentiate in various cell types
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Chapter 1
Introduction

Summary
Epicardial Derived Cells (EPDCs) can differentiate into various cell types and
migrate to be recruited in the periphery of endothelial vessels and as part of the fibrous
skeleton of the heart. The ability of EPDCs to differentiate into multiple cell types suggests
the potential implication for these cells in heart repair. Many scientists are attempting to
learn about the developmental pathways required to activate them in the adult heart. The
mechanisms that regulate the differentiation and migration of EPDCs are poorly understood.
The work in this thesis led to the discovery of a new developmental pathway that regulates
EPDC migration and indirectly myocardial proliferation. The observation that embryos
lacking a splice variant of FGF receptor 2 that is expressed in the epicardium have small
hearts suggested that a signal to the epicardium is required to control heart size. This
phenotype prompted us to look closely at the development of the epicardium. To inv estigate
the underlying mechanisms we studied heart development in embryos lacking epicardial
FGF receptors and FGF ligands that could signal to these receptors. Our findings suggests
that that growth of the myocardium is directly linked to decreased numbers of EPDCs. In
addition these studies identify a signaling pathway that specifically regulates migration of
epicardial-derived cardiac fibroblasts and supports a hypothesis that EPDC lineages within
the myocardium are independently regulated by distinct growth factor signaling pathways.
These findings are an important contribution to the understanding of heart development
because it provides a basis to support the hypothesis that smooth muscle cell and cardiac
fibroblast require the induction of independent signals to migrate into the myocardium.
Elucidating which other signals promote the migration of smooth muscle cells versus
cardiac fibroblast could lead to a comprehensive understanding of epicardial cell activation.
2

This understanding is necessary to further design functional experiments to manipulate
epicardial cells for heart repair. Below I summarize the literature on epicardial origins,
development, differentiation, migration and function within the heart. In addition, I examine
mechanisms of FGF signaling, heart development, the known functions of FGF in heart
development and finally focus specifically on discussing the developmental process
regulating the formation of the epicardium and epicardial derived cells.
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Overview of the Fibroblast Growth Factor Family
The mouse family of Fibroblast Growth Factors (FGFs) is large and diverse. It is
comprised of the intracellular FGFs (iFGFs), the canonical FGFs and the hormone -like
FGFs (hFGF) (Itoh and Ornitz, 2008). The members of the iFGF family are: Fgf11, Fgf12,
Fgf13 and Fgf14 (Smallwood et al., 1996). Intracellular FGFs are similar in sequence and
structure to canonical and hormone-like FGFs but differ in function (Olsen et al., 2003).
iFGFs exert their function inside the cell where they are known to bind to sodium channels
and modulate neuron excitability (Laezza et al., 2007; Laezza et al., 2009; Lou et al., 2005;
Xiao et al., 2007). It has been proposed that an iFGF-like protein was the common ancestor
to all known FGFs. Unlike the intracellular FGFs, which do not bind to FGF receptors, the
canonical and hormone-like FGFs are secreted outside the cells (Hanneken et al., 1994).
These are able to signal by the binding of receptor tyrosine kinases from the FGF family of
receptors (Rudland et al., 1974). The subfamily of hFGF is comprised of Fgf15 (being
Fgf19 its ortholog in humans), Fgf21 and Fgf23 (Kharitonenkov et al., 2005).
Hormone-like FGFs are thought to arise in a recent event of vertebrate evolution; as
a result they lost their high affinity for binding heparin and acquired their endocrine
characteristics. A unique feature of hFGFs is the necessity of the cofactors αKlotho and
βKloto to enhance signaling through FGF receptors (FGFR) (Kurosu and Kuro, 2009). In
contrast, canonical FGFs signal in an autocrine/paracrine fashion due to their high affinity
for heparan sulfate (Ornitz and Leder, 1992).
Canonical FGFs can be divided in the following subgroups based on sequence
similarity: FGF1 subfamily (comprised of: Fgf1, Fgf2), FGF4 subfamily (comprised of:
Fgf4, Fgf6 and Fgf5), FGF7 subfamily (comprised of: Fgf3, Fgf7, Fgf10 and Fgf22) and
4

FGF8 subfamily (comprised of: Fgf8, Fgf17) (Ornitz, 2003). Canonical FGFs signal through
FGF receptor tyrosine kinases (which are: Fgfr1, Fgfr2, Fgfr3 and Fgfr4) (Coutts and
Gallagher, 1995). FGF receptors have a unique structure composed of three main parts: the
extracellular region with three characteristic immunoglobulin-like domains, a single
transmembrane domain, and a cytoplasmic domain containing the tyrosine kinase activity
(Baird et al., 1988). The mRNA of the receptors bears an alternative splicing site that
produces the “c-splice variants” and the “b-splice variant” of receptors Fgfr1, Fgfr2 and
Fgfr3 but not of Fgfr4 (Fujita et al., 1991).
It has been consistently observed that the c-splice variant is preferentially expressed
in mesenchymal-like tissues and the b-splice variant is preferentially expressed in epitheliallike tissues. The ability of the receptors to undergo alternative splicing confers tissue and
ligand binding specificity to the signal, making it ideal to control interactions between
epithelia and mesenchyme during development (Yeh et al., 2003). To complement the
specific pattern of expression of the receptor splice variants, the FGF ligands found within
subgroups have higher affinity for specific receptors splice variants (Ornitz et al., 1996).
For example, the members of the Fgf7 family bind FGFR2b with high affinity but do not
bind FGFR2c. Ligands within a subfamily and corresponding receptors of the same splice
variantare typically found to be expressed simultaneously in adjacent tissues. Ontogeny
requires a precise and fine-tuned network of signals to orchestrate the formation of a default
outcome; therefore, continued monitoring of signal transduction is necessary to achieve the
default state. The complementary expression of FGF ligands and receptors in epithelial and
mesenchymal tissues allow the formation of signaling feedback loops that provide a way to
monitor the timing, frequency and strength of FGF developmental interaction, ensuring
5

proper regulation of tissue development and morphogenesis (Niswander et al., 1994; Zhang
et al., 2006).
The ligand binding domain is located at the second and third immunoglobulin
domain of the FGF receptors (Mohammadi et al., 2005). Although the mechanism is still
under investigation, one accepted mechanism of ligand binding is referred to as the “Ligand
Dimer“. In this mechanism, activation of the receptor occurs when one FGF ligand binds to
the cell surface heparin sulphate proteoglycan (HSPG) chain and simultaneously induce s
receptor dimerization (Ornitz et al., 1995). Receptor dimerization causes a conformational
change at the intracellular domain that activates the phosphotyrosine kinase and leads to
trans-autophosphorilation of the cytoplasmic tails as they come closer to each other (Bae et
al., 2010). Activation of the phosphotyrosine binding domain (PTB) in FGFR
phosphorylates the scaffolding protein FRS2; this leads to the recruitment of other proteins
that will activate downstream effector pathways (Zhang et al., 2008). Recruitment of SOS
and GRB2 leads to activation of the downstream pathway RAS/MAPK (Kouhara et al.,
1997). On the other hand, recruitment of GAB1 leads to the activation of downstream
pathway PI3K/AKT (Ong et al., 2001). A different activation mechanism distinct from
FRS2 is the recruitment of PLCγ to a different phosphotyrosine residue within the FGFR
cytoplasmic tail which leads to activation of PKC and strengthens the MAPK pathway
transduction by phosphorylating RAS (Mohammadi et al., 1991).
Regulation and modification of the FGF signal can occur at various levels of the
signaling pathway to render context-dependent signaling. First, the restricted pattern of
expression of the ligands, as well as the receptors, limits possible promiscuous interactions.
Second, the alternative splicing of the receptors results in selective affinity of ligand 6

receptor binding. Third, the interaction of the heparan sulfate proteoglycan with the receptor
and ligand can modulate strength and specificity of signal as well as cell type-specific
interaction due to the diverse spatial and temporal expression of the many types of HSPG.
Finally, the Sprouty proteins can modulate FGF signaling by suppressing the MAPK
transduction pathways in a feedback loop dependent manner (Lo et al., 2006). The FGF
signal is interpreted based on the spatial-temporal and cellular context of the cell activated
(Sivak et al., 2005). The activation of FGF signaling could cause changes in proliferation,
differentiation, migration and survival. In this thesis, I investigate functions of FGF10,
FGFR2b and FGFR1b in epicardial cells, the outermost layer of the heart.

7

Overview of Heart Development
The heart is the first organ to develop in the mammal and is required to provide
oxygen and nutrient exchange to the growing embryo (Rudolph, 2010). Much research has
focused on studying the origins of the cells that make up the heart. Un-committed precursor
cells of the heart have been mapped to the primitive streak (Garcia-Martinez and
Schoenwolf, 1993). Gastrulation at the primitive streak leads to the migration of the precardiac mesoderm to the anterior side of the embryo (Christiaen et al., 2010). The cardiac
mesoderm organizes into two groups of cells in each side of the midline (Nakajima et al.,
2009). These cells form the primary heart field (PHF) that later comes together at the
midline to form the primary tubular heart (Ramsdell and Yost, 1999).
A secondary heart field originally located below the PHF contributes more cells to
the arterial and venous poles of the tubular heart (Moorman et al., 2007; Vincent and
Buckingham, 2010). The tubular heart loops to the right, leading its posterior region to the
anterior side of the embryo. Looping combined with myocardial expansion leads to t he
shaping of the cardiac chambers (Taber et al., 2010). Soon after heart looping, another cell
population originates at the sinuous venosus — the proepicardium — and travels to the heart
to form the epicardial layer (Dettman et al., 1998). Another sprouting of cells from the
sinous venosus but distinct from the proepicardium differentiates to the endothelial cells of
the coronary vessels (Red-Horse et al., 2010). As development continues, endocardial cells
lining the heart lumen undergo epithelial to mesenchymal transition (EMT) to give rise to
the cardiac jelly and cardiac cushions (Person et al., 2005). Rapid growth of the
myocardium aids with the formation of the chamber septa, these are the interventricular and
atrial septae. Another population of cells from the neural crest travels though the pharyngeal
8

arches into the outflow tract (OFT). These cells contribute to form the septation in the
pulmonary trunk and aorta. These cells also contribute to form the electrical network of the
heart (Brown and Baldwin, 2006).

9

FGF Function in Heart Development
FGF signaling is important during different events in heart development. Initially,
expression of FGF ligands and FGF receptors was observed within the developing heart,
suggesting a putative role for these molecules (Zhu and Lough, 1996). Early on it was
shown that FGF2 was expressed in stage six of the chicken embryo and that Fgf2 antisense
oligonucleotides could inhibit proliferation of cultured pre-cardiac anterior avian mesoderm
(Sugi et al., 1993). Proliferation of pre-cardiac mesoderm is known to be important in the
generation of the tubular heart. Likewise expression of FGF1 and FGF4 were reported in the
chicken myocardium from stages eleven to twenty four (Zhu et al., 1996). Expression of
Fgf7 was also reported in cardiomyocytes as early as embryonic day 10.5 (E10.5) but to
date no functional in vivo evidence has been examined to attribute a role of FGF7 in heart
development (Mason et al., 1994).
The first in vivo evidence of FGF signaling controlling myocyte proliferation came
from a study in chicken where an Fgfr1 dominant negative retroviral vector introduced
during the first week of chicken development was able to decrease myocardial proliferation
(Mima et al., 1995). FGF signaling was further implicated in heart development when a null
mutant embryo of Heartless, a Drosophila FGF receptor homolog was found unable to
induce the pre-cardiac mesoderm and yielded a heartless fly (Beiman et al., 1996).
Similarly, in vertebrates, Fgf8 was found to be expressed in the cardiac endoderm that lays
contiguous with the cardiac-mesoderm. Physical removal of this endoderm caused
downregulation of cardiac markers; complementary to this observation, external addition of
FGF8 could restore the expression of these markers (Alsan BH, 2002). After the discovery
of the secondary heart field in 2001 it was shown that expression of an Fgf10 enhancer trap
10

bearing β-galactosidase mapped myocytes derived from the secondary heart field in the OFT
and right ventricle (Waldo et al., 2001). This observation suggested that FGF10 expressing
cells were exclusively part of the secondary heart field lineage proposed to be of
independent origin from the PHF (Kelly et al., 2001). Although these studies implicated a
role for FGF8 and FGF10 in development and expansion of the cardiac fields, Fgf8 null
mutants only displayed disruption in OFT and right ventricle formation but no ma jor defect
in heart development and Fgf10-/- only showed a defect in abnormal positioning of the
ventricular apex. Recent studies conditionally knocking both Fgf8 and Fgf10 from the
mesoderm confirmed that these ligands have overlapping functions at the secondary heart
field and gene dosage is important for the penetrance of OFT defect and pharyngeal arch
artery formation (Watanabe et al., 2010). Specific SHF deletion of Fgf8 and FGF receptors
have also been generated to conclude that FGF signaling in the SHF acts in an autocrine
manner.
Similarly to its functional effects in early heart development, FGF signaling
functions in other stages of heart development. For example, it has been found that Fgf4
expressed in cardiac cushion mesenchyme can cause proliferation of these cells.
Microinjection of Fgf4 protein in vivo to chicken embryos resulted in increased proliferation
of cushion mesenchyme, providing evidence of functional requirement of Fgf4 during this
process (Sugi et al., 2003). Heart growth can happen by proliferation of cardiac myocytes
and other cell types within the heart or by cellular hypertrophy. Proliferation of
cardiomyocytes is the preferred mechanism of heart growth during heart development. It has
been postulated that two significant myocardial expansions happen after heart looping. One
happens immediately after looping and another one during late gestation (Lavine and Ornitz,
11

2008). The midgestational bout of myocardial proliferation happens simultaneously with
the formation of the epicardial layer (Lavine and Ornitz, 2008). This coincident
development has been proposed to be part of the mechanism of myocardial proliferation
during midgestation. The epicardium is considered a center of proliferative signals for the
myocardium (Sucov et al., 2009).
The first observation pointing to such a mechanism came from studies of the retinoic
acid receptor alpha (RXRα). Deletion of this receptor resulted in hypoplastic ventricles.
RXRα was shown to function in the epicardium and proposed to regulate secretion of
growth factors from the epicardium that in turn could stimulate myocardial proliferation
(Chen et al., 2002). These growth factors were later determined to be FGF9 and FGF16.
Studies characterizing the Fgf9-/- embryos revealed these embryos had a small heart due to a
decrease in myocardial proliferation. Complementary deletion of both Fgfr1 and Fgfr2
specifically in the myocardium recapitulated the phenotype observed in Fgf9-/-hearts.
Moreover, FGF9 and FGF16 were found to be expressed in the epicardium and
endocardium, leading to the hypothesis that FGF signaling contributions from epicardium
and endocardium regulate cardiac growth during midgestation (Lavine et al., 2005).
Consistent with these findings Fgf16-/- hearts also display decreased embryonic proliferation
consistent with a synergistic role with FGF9 during heart development (Hotta et al., 2008).
Another important role of FGF signaling during midgestation is that it regulates the timing
of formation of the primitive vascular plexus by indirectly activating SHH signaling. It is
still unknown how FGF regulates SHH in the epicardium (Lavine et al., 2006).
FGF signaling is also important during homeostasis and maintenance of the adult
heart. The earliest observation of FGF function in the adult heart came from studies of gene
12

expression. For example, expression of different FGF ligands in cardiomyocytes was
observed after induced cardiac stenosis (Bernotat-Danielowski et al., 1993). These data
suggested that FGF signaling was required during heart homeostasis. More recently , FGF2
has become the center of much research since it has been found to have cardioprotective
capabilities (Kardami et al., 2007). The cardioprotectiveness by FGF2 was first observed in
isolated models of ischemia-reperfusion. In this study, administration of FGF2 after
ischemia lead to improvements in mechanical function (Padua et al., 1995). Consistent with
the observed protective role of FGF2 during heart ischemia, transgenic hearts
overexpressing Fgf2 displayed higher myocyte viability (Sheikh et al., 2001).
Overexpression of FGF2 was also protective in cardiac infarct models (House et al.,
2003; House et al., 2005; House et al., 2007). Administration of FGF2 to myocardial
infarcted hearts resulted in a decrease of ischemia activated cell dead and arrhythmias.
FGF2 can be translated in two different isoforms; one is low molecular weight FGF2 (loFGF2), and the other is high molecular weight FGF2 (hi-FGF2) (Liao et al., 2009). The
specific role of each isoform in cardioprotection is unclear (Liao et al., 2007). Currently,
knockouts for both isoforms have been generated for cardioprotection. Both isoforms have
similar effects immediately after acute ischemia. The main difference found was that hi FGF2 had a stronger induction of PKCδ and p70 S6 kinases (Jiang et al., 2009). Another
possible FGF involved in adult heart homeostasis is FGF16. Interest in FGF16 has increased
due to its expression peak in the perinatal heart. Particularly intriguing is the existence of an
NF-κB element in FGF16’s promoter sequence. The NF-κB site has been found to be
responsive to NF-κB induction by isoproterenol, suggesting that it could be activated upon
NF-κB binding (Sofronescu et al., 2010).
13

Overview of Epicardial Development
Epicardial development initiates with the formation of the proepicardium (Figure 1).
Development of the proepicardium has been studied in: Xenopus laevis, zebrafish,
Acipenser naccari and mammals, suggesting that it is an evolutionarily conserved biological
process. (Icardo et al., 2009; Jahr et al., 2008; Serluca, 2008). The proepicardium is a
cauliflower-like bundle of cells located anterior to the inflow of the heart (Nesbitt et al.,
2006). Proepicardial cells travel to the atrioventricular grove of the heart. Further migration
over the myocardial surface results in the formation of the epicardial mantle (Mikawa and
Gourdie, 1996). These now-termed epicardial cells undergo an epithelial to mesenchymal
transition to invade the myocardium where they differentiate into cardiac fibroblast and
vascular smooth muscle cells.
Proepicardial and epicardial cells have the potential to differentiate into various cell
types, making them plausible candidates to elicit repair in the adult heart (Winter and
Gittenberger-de Groot, 2007). Studies have tried to trace the lineage of the proepicardial
cells. Using Cre-loxP lineage tracing it was observed that proepicardial cells are derived
from Nkx2-5 and Isl1 progenitors (Zhou et al., 2008b). Consistent with this observation,
Nkx2-5 null mutants fail to form a proepicardial structure, in contrast, the proepicardium
forms in the Isl1 knockout mice. Similar to Nkx2-5-/- the Gata4-/- do not form a proepicardial
organ, as a result the heart does not develop an epicardial layer (Watt et al., 2004). These
studies give insight into the lineage origin of proepicadial cells, but do not elucidate how
proepicardial cells are specified to the proepicardial fate from myocardial prec ursors (van
Wijk and van den Hoff, 2010). Recent studies in chicken indicated that a balance between
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BMP2 and FGF2 signaling is responsible for the early separation between myocardial
progenitors and proepicardial progenitors (van Wijk et al., 2009). BMP is responsible for
driving myocardial cell fate and FGF is responsible for driving proepicardial cell fate.
Once proepicardial cells are specified, they express markers for Wt1, TBX18, TCF21
and capsulin, amongst others (Hatcher et al., 2000; Lu et al., 1998; Moore et al., 1999; Robb
et al., 1998). Expression of these markers was used as a symbol of lineage commitment in
zebrafish studies. These studies suggested that TBX5a and BMP4 are important for
proepicardial commitment (Hatcher et al., 2004). Mutant fish of either tbx5a or acvr1l (the
receptor for BMP4) repressed expression of proepicardial markers TCF21 and TBX18.
Normal expression of BMP4 in tbx5a mutants lead to the hypothesis that TBX5a promotes
competency of the lateral plate mesoderm to commit to the proepicardial cell fate.
Complementary BMP4 signaling was responsible for guaranteeing their commitment later
on (Liu and Stainier, 2010).
Proepicardial development has been studied in chickens and in mice, therefore, it is
important to mention key differences between proepicardial and epicardial development
between these species. In the chicken, the proepicardium develops from bilaterally
symmetrical buds of proepicardial cells that form a final asymmetrical structure on the right
side of the embryo (Nahirney et al., 2003). In the mouse, both proepicardial buds develop
uniformly and symmetrically (Schulte et al., 2007). FGF8 and Snail1 were found to control
the left-right (L-R) asymmetry of the chicken proepicardium. Inhibition of snail in the right
side prevented proepicardial formation. Overexposure of FGFR1 and FGF8 on the left side
of the proepicardial field was sufficient to drive ectopic proepicardial formation (Schlueter
and Brand, 2009). Proepicardial asymmetry is lost in the mouse, but it would be interesting
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to investigate if manipulation of these signals could generate an asymmetric proepicardium
in the mouse.
Once the proepicardium has been specified and formed, proepicardial cells have
been reported to express markers of different cell fates. Although it is not proven yet, this
observation has promoted the idea that cells within the proepicardium are already specified
to become cardiac fibroblast or smooth muscle cells prior to their migration to the
epicardium. Another possibility is that EPDCs differentiate as they migrate into the
myocardium. More research in this area of epicardial development is needed to discern
which of these two possibilities is correct.
Migration of proepicardial cells to the atrioventricular grove has been studied in
chickens and mice using SEM and histological analysis. In chickens, proepicardial cells
start migrating at stage HH14 and form an extracellular matrix bridge made of
proteoglycans, heparin sulfate and fibronectin that guides the proepicardial cells into the
heart (Nahirney et al., 2003). Migration of proepicardial cells in mouse starts at E9. In areas
of the proepicardium that are closest to the bare myocardium, cells start to swell and form
multicellular villous clusters that extend towards the heart. Once these clusters have
achieved sufficient length to contact the heart, the tip of the cluster touches the nude
myocardium. Beating pulls the tip off the cluster leaving the epicardial cells attached to the
myocardium. Villous tips detach and float to reach the myocardium at areas where its
unable to touch and attach to the nude myocardium (Rodgers et al., 2007).
Very little is known about the molecules directing the migration of proepicardial
cells towards the myocardium. Evidence that adhesion is important for proepicardial
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migration can be found in the phenotype of the integrin α4β1 knockout mouse. α4β1 is a
cell adhesion molecule. α4β1 null mice display defects in villous budding (Sengbusch et al.,
2002). VCAM1, the ligand for α4β1, can recapitulate the defects seen in the receptor null
embryos (Pae et al., 2008). Another molecule that presents a similar phenotype when
inactivated is RXRα. This nuclear receptor has been found to have a role during
proepicardial migration. Proepicardial cells of Rxrα−/− hearts have a higher rate of apoptosis
compared to controls and display a decreased number of villous clusters contacting the
myocardium. Furthermore, formation of the epicardial layer is disrupted due to detachments
of epicardial cells and incomplete coverage of the myocardium. These defects could be
attributed to a decreased number of epicardial cells migrating to envelop the heart (Jenkins
et al., 2005). Deletion of the glycoprotein Podoplanin results in a smaller proepicardial
organ, which impairs migration of proepicardial cells, upregulates ecadherin at the
epicardium and results in decreased amounts of Epicardial Derived Cells within the
myocardium (Mahtab et al., 2009). Also, both overexpression and repression of TBX5 in
chicken leads to inhibition of proepicardial migration to cover the myocardium (Hatcher et
al., 2004).
After proepicardial cells have migrated, they need to cover the heart and attach their
basement membrane to the myocardium. It is hypothesized that adhesion molecules are
important to mediate attachment of the epicardial layer to the myocardium. Interestingly, in
addition to problems of proepicardial migration disruption of α4β1, VCAM1, rxrα,
podoplanin and tbx5 function also results in problems adhering to the nude myocardium.
Typically, a characteristic phenotype of epicardial detachment is the formation of epicardial

17

sacs that lack direct contact between the epicardium and the myocardium (Jenkins et al.,
2005; Pae et al., 2008; Sengbusch et al., 2002).
After the epicardium has covered the heart and properly adhered to the myocardium,
a subset of epicardial cells undergo epicardial to mesenchymal transitions. Epicardial cells
become mesenchymal and delaminate into the subepicardial mesenchyme (Gittenberger-de
Groot et al., 2010; Perez-Pomares et al., 1998). Once in the subepicardial mesenchyme,
epicardial derived cells migrate further into the myocardium. These cells are named EPDCs.
The observation that epicardial mesenchyme gives rise to a large part of the adult
heart was made during the 1990s by several different laboratories using clonal retrovirals to
trace the lineage of these cells (Dettman et al., 1998; Mikawa and Gourdie, 1996; PerezPomares et al., 1997). EPDCs differentiate into vascular smooth muscles cells and pericytes
which outline the endothelial vascular plexus. They also give rise to interstitial fibroblasts, a
cell type that has been shown to control myocyte proliferation (Weeke-Klimp et al., 2010).
Therefore, failure to properly adhere to the myocardium, undergo EMT, migrate into the
myocardium and differentiate could result in cardiac heart defects. Researchers in the field
are trying to elucidate how epicardial cells become activated and competent to undergo
EMT. Canonical EMT occurs by the dissolution of cell-cell junctions, loss of apical-basal
polarity, and finally the modification of cytoskeletal proteins to a mesenchymal phenotype
that permits — in the case of epicardial cells — to coalesce within the subepicardial space
(Thiery et al., 2009).
It is not known yet if epicardial EMT happens throughout canonical mechanisms of
EMT. The epicardium as discussed earlier is not a typical epithelial tissue because its
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lineage is traced to a mesothelial origin. Support for this view comes from data identifying
expression of mesenchymal markers like vimentin in the epicardial layer (Wu et al., 2010).
In an effort to understand epicardial EMT various laboratories have looked at prototypical
proteins of EMT in the epicardium. Downregulation of e-cadherin is considered a hallmark
event to initiate EMT. In the epicardium it has been found that upregulation of e-cadherin
leads to disruption of epicardial EMT. Two molecules in the epicardium seem to regulate ecadherin expression, VCAM1 and Wt1. VCAM1 was observed to promote the epithelial like state of epicardial cells by decreasing the generation of stress fiber and maintaining
expression of e-cadherin. The effects of VCAM1 in epicardial cells were found to
counteract the EMT promoting effects of TGFβ3 (Dokic and Dettman, 2006). The other
molecule found to regulate epicardial EMT though modulation of e-cadherin expression is
Wt1. Mouse embryos lacking Wt1 specifically in the epicardium by deletion with Gata5Cre
were found to have defects in EMT yielding a smaller heart and malformation of the
coronary vessels. Hearts lacking Wt1 were shown to have an increase in amounts of e cadherin expression within the epicardial layer, suggesting that downregulation of ecadherin is important for Wt1-induced EMT. Wt1 binding sequences were found within the
e-cadherin promoter and ChIP analysis confirmed the existence of the interaction in vivo.
Additionally, Wt1 directly binds and regulates expression of Snail1, another gene that is
typically involved in canonical EMT (Martinez-Estrada et al., 2010). Other known
regulators of EMT are found to be expressed in the epicardial layer. For example , Slug is
expressed in all cells of the epicardium and it has been proposed to promote competency of
epicardial cells to undergo EMT, but no functional experiments have been done to prove
this hypothesis (Carmona et al., 2000). Another regulator or epicardial EMT in chicken is
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ETS1/2. Antisense oligonucleotides for ETS1/2 halted EMT of epicardial cells and lead to
multiple cardiac defects including a thinner myocardium. Growth factors have also been
shown to control epicardial EMT (Lie-Venema et al., 2003). TGFβ signaling has been
implicated in modulating EMT of epicardial cells, but it is not yet clear whether it
stimulates or inhibits EMT since studies from different researchers are contradictory.
Studies in the chicken embryo showed that addition of TGFβ2 and TGFβ3 inhibit EMT of
epicardial monolayers and EMT of explanted hearts. This contrasts with other results that
showed that treatment with TGFβ3 to chicken explanted hearts activated EMT. It is
important to mention that most studies suggested that TGFβ signaling promotes EMT and
inhibits the epicardial phenotype (Compton et al., 2006; Dokic and Dettman, 2006;
Morabito et al., 2001). These findings support the idea that epicardial EMT occurs via a
canonical EMT mechanism. Recent reports on the effect of β-catenin in epicardial EMT
argue that asymmetrical cell division is part of the mechanism. β-catenin epicardial
knockouts were found to have decreased amounts of EMT causing defects in cardiac
morphology. This decrease in EMT was due to the structural effect of β-catenin in
regulating the spindle orientation of epicardial asymmetrical divisions (Wu et al., 2010).
This data taken together raises new questions. How are the mechanisms of asymmetrical cell
division coupled with the prototypical mechanisms of EMT? Traditionally defects in
epicardial EMT have been interpreted in the field as a failure of the epicardial -derived cell
to coalesce into the subepicardium and/or invade the myocardium. This interpre tation makes
it very difficult to distinguish between varied phenotypes that could account for this result.
For example, EMT defects, migration defects or both. Another interesting question is what
could be the role, if any, of the subepicardial mesenchyme during EMT?
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Subsequent to EMT, the epicardial derived cell migrates further into the myocardium
to reach their final destination within the heart architecture. Smooth muscle cells and
pericytes migrate to the periphery of the coronary vessels and the interstitial fibroblasts
migrate within the cardiac myocytes. Mechanisms regulating this migration are poorly
understood. One could imagine that these cells require a very complicated array of signals
to move toward their final destination. These signals should control polarity, differentiation
and chemotacticity of the EPDCs. Not to mention that the length of the migration could , in
certain cases, be very long; therefore, extended mechanisms of induction are required to
reach the final developmental goal. Very few researchers have examined the mechanisms of
epicardial-derived cells migration. One researcher showed that absence of connexin 43
caused decrease migration of EPDCs. This was due to the disruption of cell polarity (Rhee
et al., 2009). The obstruction of migration in these cells leads to secondary heart
malformations. The final fate of cells lacking connexin43 was not determined. PDGFRβ was
also found to regulate epicardial-derived cell migration (Mellgren et al., 2008). Defects in
formation of the coronary vessels and absence of regional vascular smooth muscle in hearts
with epicardial deletion of PDGFRβ lead to the hypothesis that PDGFRβ is important for
migration of specifically vsmcs. Expression of EphrinB1 and EphrinB3 localized to the
epicardium of the chick embryo. Explant cultures of epicardial monolayers treated with
EprhinB1 was able to induce migration of the monolayer (Wengerhoff et al., 2010).
Many questions arise from these experiments. How is migration of smooth muscle
cells versus interstitial fibroblast directed towards different compartments of the heart?
When does terminal differentiation of EPDCs occur? Are the epicardial derived cells
predetermined to a cell fate before undergoing EMT? What are the signals that direct
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differential migration and differentiation of migratory EPDCs? How do epicardial-derived
smooth muscle cells couple their insertion into the coronary vessels’ architecture and vice
versa? What is the function of the epicardial-derived interstitial fibroblast during
development and after? Importantly, many of the molecules found to play a role in
epicardial mesenchymal transformation or migration have also been implicated in regulating
differentiation of these cells into smooth muscle cells, but none have been correlated with
the generation of cardiac fibroblast (Mahtab et al., 2009; Mellgren et al., 2008; Wengerhoff
et al., 2010). It is important to mention that epicardial-derived cells also have been found to
give rise to cardiac muscle in mice. Recently, two labs reported that epicardial-derived cells
in the mouse could give rise to myocardial cells. They used inducible Cre-Loxp lineage
tracing to follow the fate of the epicardial cells in mouse embryos. Although their
conclusions are very interesting, the results are controversial because the Cre markers used
are not exclusive to the epicardium and continue to be expressed in the mouse heart at later
stages (Cai et al., 2008; Zhou et al., 2008a).
Previously, I mentioned that the developing heart has different mechanisms to induce
myocardial proliferation throughout development. During midgestation, for example, FGFs
emanating from the epicardium activate FGF receptors directly in the cardiac myocytes to
induce proliferation (Lavine et al., 2005). Little was known about the mechanism of cardiac
expansion during the late embryonic stages. However, it was recently shown that cardiac
fibroblasts are required for the rapid proliferation of cardiomyocytes during late gestation. A
surge in the development of embryonic cardiac fibroblast correlates with the late gestation
cardiac myocyte proliferation. Srivastava et al showed that embryonic cardiac myocytes , but
not adult cardiac myocytes, could induce myocardial proliferation. It was elucidated that
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fibronectin and collagen produced by the cardiac fibroblast signals to the cardiac myocyte
through binding the β1 integrin receptor. This interaction is promoted by HBEGF produced
by cardiac fibroblast. This data point to HBEGF as the growth factor needed during late
gestation to induce myocardial proliferation. Conditional deletion of β1 integrin in the
myocardium lead to the formation of a smaller heart suggesting that the interaction between
ECM and β1 integrin is seminal to cardiomyocyte proliferation during late embryonic
development (Ieda et al., 2009). Interestingly, the major source of embryonic cardiac
fibroblasts is provided by the epicardial-derived cells. Furthermore, epicardial EMT and
migration occurs actively from E13.5 to E17.5 in the embryo which correlates with the time
of ventricular compaction. As with the myocardial knockout of β1 integrin, many mouse
models of proteins defective in epicardial EMT and migration mentioned previously develop
a smaller heart. This observation suggests that the amount of embryonic cardiac fibroblasts
migrating into the heart might be critical to reach the proper size of the heart. The role of
cardiac fibroblasts during heart development is not well studied. In the adult, cardiac
fibroblasts comprises the largest non-myocyte population of cells in the heart and is known
to be necessary for extracellular matrix synthesis, a very important component of the cardiac
skeleton (Snider et al., 2009).

23

References
Alsan BH, S.T. (2002). Regulation of avian cardiogenesis by Fgf8 signaling. Development
129, 1935-1943.
Bae, J.H., Boggon, T.J., Tome, F., Mandiyan, V., Lax, I., and Schlessinger, J. (2010).
Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast
growth factor receptor in living cells. Proc Natl Acad Sci U S A.
Baird, A., Schubert, D., Ling, N., and Guillemin, R. (1988). Receptor- and heparin-binding
domains of basic fibroblast growth factor. Proc Natl Acad Sci USA 85, 2324-2328.
Beiman, M., Shilo, B.Z., and Volk, T. (1996). Heartless, a Drosophila FGF receptor
homolog, is essential for cell migration and establishment of several mesodermal lineages.
Genes Dev 10, 2993-3002.
Bernotat-Danielowski, S., Sharma, H.S., Schott, R.J., and Schaper, W. (1993). Generation
and localisation of monoclonal antibodies against fibroblast growth factors in ischaemic
collateralised porcine myocardium. Cardiovasc Res 27, 1220-1228.
Brown, C.B., and Baldwin, H.S. (2006). Neural crest contribution to the cardiovascular
system. Adv Exp Med Biol 589, 134-154.
Cai, C.L., Martin, J.C., Sun, Y., Cui, L., Wang, L., Ouyang, K., Yang, L., Bu, L., Liang, X.,
Zhang, X., et al. (2008). A myocardial lineage derives from Tbx18 epicardial cells. Nature
454, 104-108.
Carmona, R., Gonzalez-Iriarte, M., Macias, D., Perez-Pomares, J.M., Garcia-Garrido, L.,
and Munoz-Chapuli, R. (2000). Immunolocalization of the transcription factor Slug in the
developing avian heart. Anat Embryol (Berl) 201, 103-109.

24

Chen, T.H., Chang, T.C., Kang, J.O., Choudhary, B., Makita, T., Tran, C.M., Burch, J.B.,
Eid, H., and Sucov, H.M. (2002). Epicardial induction of fetal cardiomyocyte proliferation
via a retinoic acid-inducible trophic factor. Dev Biol 250, 198-207.
Christiaen, L., Stolfi, A., and Levine, M. (2010). BMP signaling coordinates gene
expression and cell migration during precardiac mesoderm development. Dev Biol 340, 179187.
Compton, L.A., Potash, D.A., Mundell, N.A., and Barnett, J.V. (2006). Transforming
growth factor-beta induces loss of epithelial character and smooth muscle cell
differentiation in epicardial cells. Dev Dyn 235, 82-93.
Coutts, J.C., and Gallagher, J.T. (1995). Receptors for fibroblast growth factors. Immunol
Cell Biol 73, 584-589.
Dettman, R.W., Denetclaw, W., Jr., Ordahl, C.P., and Bristow, J. (1998). Common
epicardial origin of coronary vascular smooth muscle, perivascular fibroblasts, and
intermyocardial fibroblasts in the avian heart. Dev Biol 193, 169-181.
Dokic, D., and Dettman, R.W. (2006). VCAM-1 inhibits TGFbeta stimulated epithelialmesenchymal transformation by modulating Rho activity and stabilizing intercellular
adhesion in epicardial mesothelial cells. Dev Biol 299, 489-504.
Fujita, H., Ohta, M., Kawasaki, T., and Itoh, N. (1991). The expression of two isoforms of
the human fibroblast growth factor receptor (flg) is directed by alternative splicing.
Biochem Biophys Res Commun 174, 946-951.
Garcia-Martinez, V., and Schoenwolf, G.C. (1993). Primitive-streak origin of the
cardiovascular system in avian embryos. Dev Biol 159, 706-719.

25

Gittenberger-de Groot, A.C., Winter, E.M., and Poelmann, R.E. (2010). Epicardium-derived
cells (EPDCs) in development, cardiac disease and repair of ischemia. J Cell Mol Med 14,
1056-1060.
Hanneken, A., Ying, W., Ling, N., and Baird, A. (1994). Identification of soluble forms of
the fibroblast growth factor receptor in blood. Proc Natl Acad Sci USA 91, 9170-9174.
Hatcher, C.J., Diman, N.Y., Kim, M.S., Pennisi, D., Song, Y., Goldstein, M.M., Mikawa, T.,
and Basson, C.T. (2004). A role for Tbx5 in proepicardial cell migration during
cardiogenesis. Physiol Genomics 18, 129-140.
Hatcher, C.J., Goldstein, M.M., Mah, C.S., Delia, C.S., and Basson, C.T. (2000).
Identification and localization of TBX5 transcription factor during human cardiac
morphogenesis. Dev Dyn 219, 90-95.
Hotta, Y., Sasaki, S., Konishi, M., Kinoshita, H., Kuwahara, K., Nakao, K., and Itoh, N.
(2008). Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart.
Developmental Dynamics 237, 2947-2954.
House, S.L., Bolte, C., Zhou, M., Doetschman, T., Klevitsky, R., Newman, G., and Schultz
Jel, J. (2003). Cardiac-specific overexpression of fibroblast growth factor-2 protects against
myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation
108, 3140-3148.
House, S.L., Branch, K., Newman, G., Doetschman, T., and Schultz Jel, J. (2005).
Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is
mediated by the MAPK cascade. Am J Physiol Heart Circ Physiol 289, H2167-2175.
House, S.L., Melhorn, S.J., Newman, G., Doetschman, T., and Schultz Jel, J. (2007). The
protein kinase C pathway mediates cardioprotection induced by cardiac-specific

26

overexpression of fibroblast growth factor-2. Am J Physiol Heart Circ Physiol 293, H354365.
Icardo, J.M., Guerrero, A., Duran, A.C., Colvee, E., Domezain, A., and Sans-Coma, V.
(2009). The development of the epicardium in the sturgeon Acipenser naccarii. Anat Rec
(Hoboken) 292, 1593-1601.
Ieda, M., Tsuchihashi, T., Ivey, K.N., Ross, R.S., Hong, T.T., Shaw, R.M., and Srivastava,
D. (2009). Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin
signaling. Dev Cell 16, 233-244.
Itoh, N., and Ornitz, D.M. (2008). Functional Evolutionary History of the Mouse Fgf Gene
Family Developmental Dynamics 237, 18-27.
Jahr, M., Schlueter, J., Brand, T., and Manner, J. (2008). Development of the proepicardium
in Xenopus laevis. Dev Dyn 237, 3088-3096.
Jenkins, S.J., Hutson, D.R., and Kubalak, S.W. (2005). Analysis of the proepicardiumepicardium transition during the malformation of the RXRalpha-/- epicardium. Dev Dyn
233, 1091-1101.
Jiang, Z.S., Wen, G.B., Tang, Z.H., Srisakuldee, W., Fandrich, R.R., and Kardami, E.
(2009). High molecular weight FGF-2 promotes postconditioning-like cardioprotection
linked to activation of the protein kinase C isoforms Akt and p70 S6 kinase. Canadian
Journal of Physiology and Pharmacology 87, 798-804.
Kardami, E., Detillieux, K., Ma, X., Jiang, Z., Santiago, J.J., Jimenez, S.K., and Cattini,
P.A. (2007). Fibroblast growth factor-2 and cardioprotection. Heart Fail Rev 12, 267-277.
Kelly, R.G., Brown, N.A., and Buckingham, M.E. (2001). The arterial pole of the mouse
heart forms from Fgf10-expressing cells in pharyngeal mesoderm. Dev Cell 1, 435-440.

27

Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath,
E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., et al. (2005). FGF-21 as a
novel metabolic regulator. J Clin Invest 115, 1627-1635.
Kouhara, H., Hadari, Y.R., Spivakkroizman, T., Schilling, J., Barsagi, D., Lax, I., and
Schlessinger, J. (1997). A Lipid-Anchored Grb2-Binding Protein That Links Fgf-Receptor
Activation to the Ras/Mapk Signaling Pathway. Cell 89, 693-702.
Kurosu, H., and Kuro, O.M. (2009). The Klotho gene family as a regulator of endocrine
fibroblast growth factors. Molecular and Cellular Endocrinology 299, 72-78.
Laezza, F., Gerber, B.R., Lou, J., Kozel, M.A., Hartman, H., Craig, A.M., Ornitz, D.M., and
Nerbonne, J.M. (2007). The Fgf14(F145S) mutation disrupts the interaction of FGF14 with
voltage-gated Na+ channels and impairs neuronal excitability. J Neurosci 27, 12033-12044.
Laezza, F., Lampert, A., Kozel, M.A., Gerber, B.R., Rush, A.M., Nerbonne, J.M., Waxman,
S.G., Dib-Hajj, S.D., and Ornitz, D.M. (2009). FGF14 N-Terminal Splice Variants
Differentially Modulate Nav1.2 and Nav1.6-Encoded Sodium Channels. Molecular and
Cellular Neurosciences 42, 90-101.
Lavine, K.J., and Ornitz, D.M. (2008). Fibroblast Growth Factors and Hedgehogs: At the
Heart of the Epicardial Signaling Center. Trends in Genetics 24, 33-40.
Lavine, K.J., White, A.C., Park, C., Smith, C.S., Choi, K., Long, F., Hui, C.C., and Ornitz,
D.M. (2006). Fibroblast growth factor signals regulate a wave of Hedgehog activation that
is essential for coronary vascular development. Genes Dev 20, 1651-1666.
Lavine, K.J., Yu, K., White, A.C., Zhang, X., Smith, C., Partanen, J., and Ornitz, D.M.
(2005). Endocardial and epicardial derived FGF signals regulate myocardial proliferation
and differentiation in vivo. Developmental Cell 8, 85-95.

28

Liao, S., Bodmer, J., Pietras, D., Azhar, M., Doetschman, T., and Schultz Jel, J. (2009).
Biological functions of the low and high molecular weight protein isoforms of fibroblast
growth factor-2 in cardiovascular development and disease. Dev Dyn 238, 249-264.
Liao, S., Porter, D., Scott, A., Newman, G., Doetschman, T., and Schultz Jel, J. (2007). The
cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2:
the role of JNK signaling. Journal of Molecular and Cellular Cardiology 42, 106-120.
Lie-Venema, H., Gittenberger-de Groot, A.C., van Empel, L.J., Boot, M.J., Kerkdijk, H., de
Kant, E., and DeRuiter, M.C. (2003). Ets-1 and Ets-2 transcription factors are essential for
normal coronary and myocardial development in chicken embryos. Circ Res 92, 749-756.
Liu, J., and Stainier, D.Y. (2010). Tbx5 and Bmp signaling are essential for proepicardium
specification in zebrafish. Circ Res 106, 1818-1828.
Lo, T.L., Fong, C.W., Yusoff, P., McKie, A.B., Chua, M.S., Leung, H.Y., and Guy, G.R.
(2006). Sprouty and cancer: the first terms report. Cancer Lett 242, 141-150.
Lou, J.Y., Laezza, F., Gerber, B.R., Xiao, M., Yamada, K.A., Hartmann, H., Craig, A.M.,
Nerbonne, J.M., and Ornitz, D.M. (2005). Fibroblast Growth Factor 14 is an Intracellular
Modulator of Voltage-Gated Sodium Channels. Journal of Physiology 569, 179-193.
Lu, J., Richardson, J.A., and Olson, E.N. (1998). Capsulin: a novel bHLH transcription
factor expressed in epicardial progenitors and mesenchyme of visceral organs. Mech Dev
73, 23-32.
Mahtab, E.A., Vicente-Steijn, R., Hahurij, N.D., Jongbloed, M.R., Wisse, L.J., DeRuiter,
M.C., Uhrin, P., Zaujec, J., Binder, B.R., Schalij, M.J., et al. (2009). Podoplanin deficient
mice show a RhoA-related hypoplasia of the sinus venosus myocardium including the
sinoatrial node. Dev Dyn 238, 183-193.

29

Martinez-Estrada, O.M., Lettice, L.A., Essafi, A., Guadix, J.A., Slight, J., Velecela, V.,
Hall, E., Reichmann, J., Devenney, P.S., Hohenstein, P., et al. (2010). Wt1 is required for
cardiovascular progenitor cell formation through transcriptional control of Snail and E cadherin. Nature Genetics 42, 89-93.
Mason, I.J., Fuller-Pace, F., Smith, R., and Dickson, C. (1994). FGF-7 (keratinocyte growth
factor) expression during mouse development suggests roles in myogenesis, forebrain
regionalisation and epithelial-mesenchymal interactions. Mech Dev 45, 15-30.
Mellgren, A.M., Smith, C.L., Olsen, G.S., Eskiocak, B., Zhou, B., Kazi, M.N., Ruiz, F.R.,
Pu, W.T., and Tallquist, M.D. (2008). Platelet-derived growth factor receptor beta signaling
is required for efficient epicardial cell migration and development of two distinct coro nary
vascular smooth muscle cell populations. Circ Res 103, 1393-1401.
Mikawa, T., and Gourdie, R.G. (1996). Pericardial mesoderm generates a population of
coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial
organ. Dev Biol 174, 221-232.
Mima, T., Ohuchi, H., Noji, S., and Mikawa, T. (1995). FGF can induce outgrowth of
somatic mesoderm both inside and outside of limb-forming regions. Dev Biol 167, 617-620.
Mohammadi, M., Honneger, A.M., Rotin, D., Fisher, R., Bellot, F., Li, W., Dionne, C.A.,
Jaye, M., Rubinstein, M., and Schlessinger, J. (1991). A tyrosine-phosphorylated carboxyterminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2
domain of phospholipase C-1. Mol Cell Biol 11, 5068-5078.
Mohammadi, M., Olsen, S.K., and Goetz, R. (2005). A protein canyon in the FGF-FGF
receptor dimer selects from an a la carte menu of heparan sulfate motifs. Curr Opin Struct
Biol.

30

Moore, A.W., McInnes, L., Kreidberg, J., Hastie, N.D., and Schedl, A. (1999). YAC
complementation shows a requirement for Wt1 in the development of epicardium, adrenal
gland and throughout nephrogenesis. Development 126, 1845-1857.
Moorman, A.F., Christoffels, V.M., Anderson, R.H., and van den Hoff, M.J. (2007). The
heart-forming fields: one or multiple? Philos Trans R Soc Lond B Biol Sci 362, 1257-1265.
Morabito, C.J., Dettman, R.W., Kattan, J., Collier, J.M., and Bristow, J. (2001). Positive and
negative regulation of epicardial-mesenchymal transformation during avian heart
development. Dev Biol 234, 204-215.
Nahirney, P.C., Mikawa, T., and Fischman, D.A. (2003). Evidence for an extracellular
matrix bridge guiding proepicardial cell migration to the myocardium of chick embryos.
Dev Dyn 227, 511-523.
Nakajima, Y., Sakabe, M., Matsui, H., Sakata, H., Yanagawa, N., and Yamagishi, T. (2009).
Heart development before beating. Anat Sci Int 84, 67-76.
Nesbitt, T., Lemley, A., Davis, J., Yost, M.J., Goodwin, R.L., and Potts, J.D. (2006).
Epicardial development in the rat: a new perspective. Microsc Microanal 12, 390-398.
Niswander, L., Jeffrey, S., Martin, G.R., and Tickle, C. (1994). A positive feedback loop
coordinates growth and patterning in the vertebrate limb [see comments]. Nature 371, 609612.
Olsen, S.K., Garbi, M., Zampieri, N., Eliseenkova, A.V., Ornitz, D.M., Goldfarb, M., and
Mohammadi, M. (2003). Fibroblast growth factor (FGF) homologous factors share
structural but not functional homology with FGFs. J Biol Chem 278, 34226-34236.
Ong, S.H., Hadari, Y.R., Gotoh, N., Guy, G.R., Schlessinger, J., and Lax, I. (2001).
Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is

31

mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S
A 98, 6074-6079.
Ornitz, D.M. (2003). Fibroblast Growth Factors: Evolution of. In Encyclopedia of the
Human Genome (New York, Nature Publishing Group), p. in press.
Ornitz, D.M., Herr, A.B., Nilsson, M., Westman, J., Svahn, C.-M., and Waksman, G.
(1995). FGF binding and FGF receptor activation by synthetic heparan-derived Di- and
Trisaccharides. Science 268, 432-436.
Ornitz, D.M., and Leder, P. (1992). Ligand specificity and heparin dependence of fibroblast
growth factor receptors 1 and 3. J Biol Chem 267, 16305-16311.
Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C.A., Coulier, F., Gao, G.,
and Goldfarb, M. (1996). Receptor specificity of the fibroblast growth factor family. J Biol
Chem 271, 15292-15297.
Padua, R.R., Sethi, R., Dhalla, N.S., and Kardami, E. (1995). Basic fibroblast growth factor
is cardioprotective in ischemia-reperfusion injury. Mol Cell Biochem 143, 129-135.
Pae, S.H., Dokic, D., and Dettman, R.W. (2008). Communication between integrin receptors
facilitates epicardial cell adhesion and matrix organization. Dev Dyn 237, 962-978.
Perez-Pomares, J.M., Macias, D., Garcia-Garrido, L., and Munoz-Chapuli, R. (1997).
Contribution of the primitive epicardium to the subepicardial mesenchyme in hamster and
chick embryos. Dev Dyn 210, 96-105.
Perez-Pomares, J.M., Macias, D., Garcia-Garrido, L., and Munoz-Chapuli, R. (1998). The
origin of the subepicardial mesenchyme in the avian embryo: an immunohistochemical and
quail-chick chimera study. Dev Biol 200, 57-68.

32

Person, A.D., Klewer, S.E., and Runyan, R.B. (2005). Cell biology of cardiac cushion
development. Int Rev Cytol 243, 287-335.
Ramsdell, A.F., and Yost, H.J. (1999). Cardiac looping and the vertebrate left -right axis:
antagonism of left-sided Vg1 activity by a right-sided ALK2-dependent BMP pathway.
Development 126, 5195-5205.
Red-Horse, K., Ueno, H., Weissman, I.L., and Krasnow, M.A. (2010). Coronary arteries
form by developmental reprogramming of venous cells. Nature 464, 549-553.
Rhee, D.Y., Zhao, X.Q., Francis, R.J., Huang, G.Y., Mably, J.D., and Lo, C.W. (2009).
Connexin 43 regulates epicardial cell polarity and migration in coronary vascular
development. Development 136, 3185-3193.
Robb, L., Mifsud, L., Hartley, L., Biben, C., Copeland, N.G., Gilbert, D.J., Jenkins, N.A.,
and Harvey, R.P. (1998). epicardin: A novel basic helix-loop-helix transcription factor gene
expressed in epicardium, branchial arch myoblasts, and mesenchyme of developing lung,
gut, kidney, and gonads. Dev Dyn 213, 105-113.
Rodgers, L.S., Lalani, S., Runyan, R.B., and Camenisch, T.D. (2007). Differential growth
and multicellular villi direct proepicardial translocation to the developing mouse heart. Dev
Dyn.
Rudland, P.S., Seifert, W., and Gospodarowicz, D. (1974). Growth control in cultured
mouse fibroblasts: induction of the pleiotypic and mitogenic responses by a purified growth
factor. Proc Natl Acad Sci U S A 71, 2600-2604.
Rudolph, A.M. (2010). Congenital cardiovascular malformations and the fetal circulation.
Arch Dis Child Fetal Neonatal Ed 95, F132-136.

33

Schlueter, J., and Brand, T. (2009). A right-sided pathway involving FGF8/Snai1 controls
asymmetric development of the proepicardium in the chick embryo. Proc Natl Acad Sci U S
A 106, 7485-7490.
Schulte, I., Schlueter, J., Abu-Issa, R., Brand, T., and Manner, J. (2007). Morphological and
molecular left-right asymmetries in the development of the proepicardium: a comparative
analysis on mouse and chick embryos. Dev Dyn 236, 684-695.
Sengbusch, J.K., He, W., Pinco, K.A., and Yang, J.T. (2002). Dual functions of
[alpha]4[beta]1 integrin in epicardial development: initial migration and long-term
attachment. J Cell Biol 157, 873-882.
Serluca, F.C. (2008). Development of the proepicardial organ in the zebrafish. Dev Biol
315, 18-27.
Sheikh, F., Sontag, D.P., Fandrich, R.R., Kardami, E., and Cattini, P.A. (2001).
Overexpression of FGF-2 increases cardiac myocyte viability after injury in isolated mouse
hearts. Am J Physiol Heart Circ Physiol 280, H1039-1050.
Sivak, J.M., Petersen, L.F., and Amaya, E. (2005). FGF signal interpretation is directed by
Sprouty and Spred proteins during mesoderm formation. Dev Cell 8, 689-701.
Smallwood, P.M., Munoz-Sanjuan, I., Tong, P., Macke, J.P., Hendry, S.H., Gilbert, D.J.,
Copeland, N.G., Jenkins, N.A., and Nathans, J. (1996). Fibroblast growth factor (FGF)
homologous factors: new members of the FGF family implicated in nervous system
development. Proc Natl Acad Sci USA 93, 9850-9857.
Snider, P., Standley, K.N., Wang, J., Azhar, M., Doetschman, T., and Conway, S.J. (2009).
Origin of cardiac fibroblasts and the role of periostin. Circ Res 105, 934-947.

34

Sofronescu, A.G., Detillieux, K.A., and Cattini, P.A. (2010). FGF-16 is a Target for
Adrenergic Stimulation Through NF-{kappa}B Activation in Postnatal Cardiac Cells and
Adult Mouse Heart. Cardiovasc Res.
Sucov, H.M., Gu, Y., Thomas, S., Li, P., and Pashmforoush, M. (2009). Epicardial control
of myocardial proliferation and morphogenesis. Pediatr Cardiol 30, 617-625.
Sugi, Y., Ito, N., Szebenyi, G., Myers, K., Fallon, J.F., Mikawa, T., and Markwald, R .R.
(2003). Fibroblast growth factor (FGF)-4 can induce proliferation of cardiac cushion
mesenchymal cells during early valve leaflet formation. Dev Biol 258, 252-263.
Sugi, Y., Sasse, J., and Lough, J. (1993). Inhibition of precardiac mesoderm cell
proliferation by antisense oligodeoxynucleotide complementary to fibroblast growth factor 2 (FGF-2). Dev Biol 157, 28-37.
Taber, L.A., Voronov, D.A., and Ramasubramanian, A. (2010). The role of mechanical
forces in the torsional component of cardiac looping. Ann N Y Acad Sci 1188, 103-110.
Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal
transitions in development and disease. Cell 139, 871-890.
van Wijk, B., van den Berg, G., Abu-Issa, R., Barnett, P., van der Velden, S., Schmidt, M.,
Ruijter, J.M., Kirby, M.L., Moorman, A.F., and van den Hoff, M.J. (2009). Epicardium and
myocardium separate from a common precursor pool by crosstalk between bone
morphogenetic protein- and fibroblast growth factor-signaling pathways. Circ Res 105, 431441.
van Wijk, B., and van den Hoff, M. (2010). Epicardium and myocardium originate from a
common cardiogenic precursor pool. Trends in Cardiovascular Medicine 20, 1-7.

35

Vincent, S.D., and Buckingham, M.E. (2010). How to Make a Heart The Origin and
Regulation of Cardiac Progenitor Cells. Current Topics in Developmental Biology 90C, 141.
Waldo, K.L., Kumiski, D.H., Wallis, K.T., Stadt, H.A., Hutson, M.R., Platt, D.H., and
Kirby, M.L. (2001). Conotruncal myocardium arises from a secondary heart field .
Development 128, 3179-3188.
Watanabe, Y., Miyagawa-Tomita, S., Vincent, S.D., Kelly, R.G., Moon, A.M., and
Buckingham, M.E. (2010). Role of mesodermal FGF8 and FGF10 overlaps in the
development of the arterial pole of the heart and pharyngeal arch arteries. Circ Res 106,
495-503.
Watt, A.J., Battle, M.A., Li, J., and Duncan, S.A. (2004). GATA4 is essential for formation
of the proepicardium and regulates cardiogenesis. Proc Natl Acad Sci U S A 101, 1257312578.
Weeke-Klimp, A., Bax, N.A., Bellu, A.R., Winter, E.M., Vrolijk, J., Plantinga, J., Maas, S.,
Brinker, M., Mahtab, E.A., Gittenberger-de Groot, A.C., et al. (2010). Epicardium-derived
cells enhance proliferation, cellular maturation and alignment of cardiomyocytes. J Mol Cell
Cardiol.
Wengerhoff, S.M., Weiss, A.R., Dwyer, K.L., and Dettman, R.W. (2010). A migratory role
for EphrinB ligands in avian epicardial mesothelial cells. Dev Dyn 239, 598-609.
Winter, E.M., and Gittenberger-de Groot, A.C. (2007). Epicardium-derived cells in
cardiogenesis and cardiac regeneration. Cell Mol Life Sci 64, 692-703.

36

Wu, M., Smith, C.L., Hall, J.A., Lee, I., Luby-Phelps, K., and Tallquist, M.D. (2010).
Epicardial spindle orientation controls cell entry into the myocardium. Dev Cell 19, 114125.
Xiao, M., Xu, L., Laezza, F., Yamada, K., Feng, S., and Ornitz, D.M. (2007). Impaired
hippocampal synaptic transmission and plasticity in mice lacking fibroblast growth factor
14. Mol Cell Neurosci 34, 366-377.
Yeh, B.K., Igarashi, M., Eliseenkova, A.V., Plotnikov, A.N., Sher, I., Ron, D., Aaronson,
S.A., and Mohammadi, M. (2003). Structural basis by which alternative splicing confers
specificity in fibroblast growth factor receptors. Proc Natl Acad Sci U S A 100, 2266-2271.
Zhang, X., Stappenbeck, T.S., White, A.C., Lavine, K.J., Gordon, J.I., and Ornitz, D.M.
(2006). Reciprocal epithelial-mesenchymal FGF signaling is required for cecal
development. Development 133, 173-180.
Zhang, Y., McKeehan, K., Lin, Y., Zhang, J., and Wang, F. (2008). Fibroblast growth factor
receptor 1 (FGFR1) tyrosine phosphorylation regulates binding of FGFR substrate 2alpha
(FRS2alpha) but not FRS2 to the receptor. Mol Endocrinol 22, 167-175.
Zhou, B., Ma, Q., Rajagopal, S., Wu, S.M., Domian, I., Rivera-Feliciano, J., Jiang, D., von
Gise, A., Ikeda, S., Chien, K.R., et al. (2008a). Epicardial progenitors contribute to the
cardiomyocyte lineage in the developing heart. Nature 454, 109-113.
Zhou, B., von Gise, A., Ma, Q., Rivera-Feliciano, J., and Pu, W.T. (2008b). Nkx2-5- and
Isl1-expressing cardiac progenitors contribute to proepicardium. Biochem Biophys Res
Commun 375, 450-453.

37

Zhu, X., and Lough, J. (1996). Expression of alternatively spliced and canonical basic
fibroblast growth factor mRNAs in the early embryo and developing heart. Dev Dyn 206,
139-145.
Zhu, X., Sasse, J., McAllister, D., and Lough, J. (1996). Evidence that fibroblast growth
factors 1 and 4 participate in regulation of cardiogenesis. Dev Dyn 207, 429-438.

38

Figure 1.

39

Figure 1.
Overview of epicardial development. (A) At E9.5 the heart is looped and the
proepicardium is a bundle of cells attached to the ventral body wall. The yellow square
marks the area zoomed in (B). (B) The heart is only composed of two layers: the
endocardium (pink) and the myocardium (cyan). Proepicardial villous cysts (red) grow
allowing proepicardial cells to contact the heart or travel through the pericardial fluid to
contact the heart. (C) Proepicardial cells migrate in a gradient from base to apex over the
surface of the heart covering it. (D) As the epicardium covers the heart, the subepicardial
mesenchyme (orange) forms to provide a space for a subset of epicardial cells to undergo an
epithelial to mesenchymal transition. The cells that undergo EMT and migrate are t ermed
EPDCs. Epicardial cells differentiate into either vascular smooth muscle cells (red) or
cardiac fibroblasts (green). Simultaneously, the primitive vascular tree formed by sprouting
of the sinous venosus also grows in a gradient from base to apex (blue). (E) The heart
continues growing and the vascular plexus remodels by incorporating the vascular smooth
muscle cells. The yellow circle and square marks a zoomed area shown in (F). (F) Shows
the lineage fate of the epicardial cells and their final location in the heart. Vascular smooth
muscle cells are recruited to the endothelial tubes and cardiac fibroblast become part of the
fibrous skeleton of the heart. (G) Legend.
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Chapter 2
FGF10/FGFR2b signaling is essential for cardiac fibroblast development and growth
of the myocardium
Mónica Vega Hernández, Attila Kovacs, Stijn De Langhe and David M. Ornitz

Abstract
The epicardium serves as a source of growth factors that regulate myocardial
proliferation and as a source of epicardial-derived cells, interstitial cardiac fibroblasts and
perivascular cells, which populate the compact myocardium. In addition to epicardialderived growth factors, such as fibroblast growth factor 9 (FGF9), cardiac fibroblasts are
also necessary for myocardial growth. The mechanisms that regulate epicardial function
during development and the mechanisms that regulate the formation of epicardial-derived
cells are poorly understood. Here, we identify a myocardial to epicardial fibroblast
growth factor (FGF) signal, mediated by FGF10 and FGFR2b that is essential for
movement of cardiac fibroblasts into the compact myocardium. Inactivation of this
signaling pathway results in fewer epicardial derived cells within the compact
myocardium, decreased myocardial proliferation and a resulting smaller, thin-walled
heart.
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Introduction
The epicardium comprises the outer layer of the heart and provides a source of
cardiac fibroblasts, vascular smooth muscle cells and pericytes during heart development
(Cai et al., 2008; Dettman et al., 1998; Marguerie et al., 2006; Merki et al., 2005; Mikawa
and Fischman, 1992 ; Mikawa and Gourdie, 1996; Snider et al., 2009). The formation of
the epicardial layer begins after heart looping at E9.5 in the mouse (Kalman et al., 1995).
Epicardial cells arise from the proepicardial organ, which is a transient structure located
close to the sinus venosus on the ventral body wall (Hiruma and Hirakow, 1989; Vincent
and Buckingham, 2010). Cells from the proepicardium migrate to the atrioventricular
groove and then from the base of the heart to the apex, covering the heart as a single cell
layer. Concurrently, a capillary plexus grows from the dorsal atrioventricular groove and
expands towards the apex and ventrally to envelope the entire heart (Kattan et al., 2004;
Lavine et al., 2006; Red-Horse et al., 2010). As epicardial cells migrate to cover the
heart, a subset of epicardial cells undergo epithelial to mesenchymal transitions (EMT)
and delaminate from the epicardium. These cells are termed epicardial derived cells
(EPDCs). Once EPDCs acquire mesenchymal phenotype they migrate further into the
compact myocardium where they differentiate into smooth muscle cells and cardiac
fibroblasts. PDFGRβ, Alk5 are factors that regulate epicardial-derived vascular smooth
muscle cells (Mellgren et al., 2008; Sridurongrit et al., 2008). In contrast, factors that
regulate migration of cardiac fibroblast have not been identified. These differentiated
smooth muscle cells and cardiac fibroblasts become part of the mature coronary
vasculature and interstitial mesenchyme of the heart.
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The FGF family is comprised of 18 signaling ligands and four receptors (FGFRs)
(Itoh and Ornitz, 2008; Ornitz and Itoh, 2001; Turner and Grose, 2010). Fgfr1, Fgfr2 and
Fgfr3 undergo alternative splicing that results in b and c splice variants (Dell and
Williams, 1992; Werner et al., 1992). The b splice variants are preferentially expressed in
epithelial and epithelial-like tissues, such as the epicardium (Marguerie et al., 2006). In
contrast, c splice variants are preferentially expressed in mesenchymal tissues. FGF
ligands are classified in subfamilies based on phylogenetic similarities. Members of each
subfamily of FGFs share similar biochemical properties, such as affinity for specific
FGFRs and FGFR splice variants (Itoh and Ornitz, 2004). FGFR2c is efficiently activated
by members of the FGF9 subfamily (FGF9, FGF16 and FGF20) (Ornitz et al., 1996;
Zhang et al., 2006). In contrast, FGF3, FGF7, FGF10 and FGF22 are ligands that activate
FGFR2b. Downstream FGF signal transduction can proceed via three main pathways:
Ras/MAPK pathway, phospholipase Cγ (PLCγ)/Ca2+ pathway, and the PI3 kinase/Akt
pathway (Eswarakumar et al., 2005; Lemmon and Schlessinger, 2010).
The expression of several FGFs and FGFRs in cardiac and vascular mesoderm,
mesothelium and endoderm suggests an important role for these molecules in
development of the heart. In zebrafish and avian models, FGF signaling has been
implicated as important for epicardial cells to undergo EMT, to enter the myocardium,
and potentially to differentiate into coronary smooth muscle cells, interstitial cardiac
fibroblasts, coronary endothelial cells and cardiomyocytes (Lepilina et al., 2006; Mikawa
and Gourdie, 1996; Morabito et al., 2001; Perez-Pomares et al., 2002). The FGF ligands,
FGF1, FGF2 and FGF7 were shown to stimulate EMT in cultured epicardial cells
(Morabito et al., 2001) and pharmacological inhibition of FGF signaling impaired
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epicardial EMT (Pennisi and Mikawa, 2009); however, retroviral expression of a
dominant negative FGFR1 in epicardial and endothelial precursors in the proepicardial
organ did not affect epicardial EMT but did impair the progeny of proepicardial-derived
cells from invading the myocardium (Pennisi and Mikawa, 2009). These studies suggest
that FGF signaling is necessary for epicardial and endothelial development but do not
define the precise FGF signaling pathways that regulate each of these lineages or
determine whether signaling is direct or indirect.
In previous studies, we identified an epicardial to myocardial FGF signaling
pathway, in which FGF9, expressed in the epicardium, signals to FGFR1c and FGFR2c
in the myocardium to control myocardial proliferation and indirectly, vascular formation
(Lavine et al., 2005). Several studies have identified expression of Fgf7 and Fgf10 in the
developing myocardium and one study showed that mice lacking the b splice variant of
Fgfr2 (Fgfr2b-/-) developed a thin-walled heart (Marguerie et al., 2006; Morabito et al.,
2001). These observations suggest that FGF signals emanating from the myocardium
might directly regulate epicardial development or function. In this study, we show that
FGF10 signals to the epicardium through FGFR1 and FGFR2b. In turn, these receptors
control movement of EPDCs into the compact myocardium. Inactivation of this pathway
results in fewer EPDCs within the compact myocardium and results in reduced
cardiomyocyte proliferation and a smaller heart.
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Results
FGF10 signaling to the epicardium regulates heart size.
The phenotype of Fgfr2b-/- mice and the presence of appropriate ligand expression
in the heart suggested that FGF signaling might regulate epicardial function and
indirectly myocardial development. Such a signal, from cardiomyocytes, fibroblast or
vascular cells in the compact myocardium may constitute a feedback loop to the
epicardium to control heart size during development. To test the hypothesis that a
myocardial to epicardial signal could regulate development of the heart, we measured the
cross-sectional area of the whole heart and the thickness of the compact myocardium in
Fgfr2b-/-, Fgf7-/- and Fgf10-/- embryos at several developmental time points. At earlier
stages (E13.5 to E15.5), Fgfr2b-/- hearts appeared normal in external morphology (data
not shown), but at embryonic day 17.5 (E17.5), Fgfr2b-/- embryos and Fgf10-/- embryos
both appeared smaller (Figure 1A-D). The width of the compact myocardium of Fgfr2b-/embryos as shown by (Marguerie et al., 2006) and Fgf10-/- embryos were significantly
(p<0.02, p< 0.003, respectively) thinner than age-matched control embryos (Figure 1A’D’). Fgf7-/- embryos did not show a significant difference in thickness of the compact
myocardium. We were able to generate two Fgf7-/-;Fgf10-/- embryos at E17.5, and the
hearts of both appeared smaller in size compared to Fgf10-/- hearts, suggesting possible
redundancy with FGF7. In utero echocardiography also showed a decrease in diastolic
wall thickness in E17.5 Fgfr2b-/- hearts when compared to control littermates (Figure 1GJ and supplemental Figure 1). Consistently, the interventricular septum of Fgfr2b-/- hearts
was also thinner (Figure 1K). We also examined the formation of coronary vessels in
Fgfr2b-/- and Fgf10-/- hearts. Endothelial vessels formed normally compared to controls
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(Supplemental Figure 2). Taken together, these data suggest that FGF10 signals to
FGFR2b during late gestation to control heart size.
Based on these phenotypes, we hypothesized that FGFR2b should be expressed in
epicardial cells and FGF10 should be expressed in cardiac myocytes or other cell-types
within the compact myocardium. In situ hybridization localized Fgf10 mRNA expression
within the myocardium of wild type hearts at E17.5 (Figure 2A-B). No expression was
observed in Fgf10-/- hearts or with a sense probe. FGFR2 protein expression was
examined using an antibody that detects both the b and c splice forms (Figure 2C-D). In
wild type hearts, FGFR2 expression was observed in both the epicardial layer and the
myocardial layer. In contrast, in Fgfr2b-/- hearts, the expression of FGFR2 was absent in
the epicardial layer but present throughout the myocardium. This expression pattern
supports a model in which myocardial derived FGF10 signals to FGFR2b in the
epicardium to control heart size. Additionally, FGF10 could signal to other unidentified
FGFR2b-expressing cells within the myocardium.
Fgfr2b-/- is a germline knockout with multiple developmental defects. Therefore,
to determine whether FGFR2 signaling in epicardial cells and EPDCs could be
responsible for the observed cardiac phenotypes in Fgfr2b-/- embryos, we used Wt1-Cre
to inactivate a floxed allele of Fgfr2 in the epicardium and in EPDCs (Figure 3). Because
FGF10 can also signal to FGFR1b and FGFR1 and FGFR2 often show functional
redundancy, we simultaneously inactivated conditional alleles of both Fgfr1 and Fgfr2.
Mice with the genotype, Wt1-Cre, Fgfr1f/f, Fgfr2f/f (referred to as Fgfr1/2Wt1-Cre) showed a
thin-walled compact myocardium similar to that seen in Fgfr2b-/- and Fgf10-/- embryos
(Figure 3E). However, mice conditionally lacking only Fgfr1 or Fgfr2 did not show a
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significant decreased wall thickness, demonstrating functional redundancy of these
receptors. In addition, total heart size in Fgfr1/2Wt1-Cre embryos was decreased compared
to heterozygous control embryos when normalized to body weight (Figure 3F). The more
severe phenotype of Fgfr2b-/- hearts, compared to Fgfr2Wt1-Cre hearts, could be a
consequence of developmental defects intrinsic or extrinsic to the heart.
To account for the observed small size of the heart in Fgfr1/2Wt1-Cre and Fgf10-/embryos, we examined myocardial proliferation and cell death. Examination of BrdU
incorporation showed a significant decrease in proliferation when compared to controls at
E15.5 and E17.5 (Figure 4) in Fgfr1/2Wt1-Cre hearts. These results suggest that FGF10
controls epicardial development or function that in turn indirectly regulates myocardial
growth. Immunostaining for active Caspase 3 expression did not show any differences
between controls and Fgfr1/2Wt1-Cre or Fgf10-/- hearts (Supplemental Figure 3).

Regulation of epicardial development by FGF signaling.
To determine whether loss of epicardial FGFR1 and FGFR2 in Fgfr1/2Wt1-Cre mice
affects epicardial development we examined the rate of proliferation of epicardial cells
and the number of epicardial-derived cells localized within the compact myocardium in
Fgfr1/2Wt1-Cre and Fgf10-/- were counted. At E17.5, there was no change in proliferation
of epicardial cells between Fgfr1/2Wt1-Cre mice and control littermates (Figure 4D). To
determine if epicardial EMT, delamination from the epicardium, or EPDC migration was
defective in Fgfr1/2Wt1-Cre and Fgf10-/- hearts, we examined the expression of Wt1, a
protein expressed in epicardial cells and EPDCs (Figure 5A-D). In control hearts at
E17.5, 15% of cells within the compact myocardium expressed Wt1. In contrast, in
Fgfr1/2Wt1-Cre and Fgf10-/- hearts there were significantly (p< 0.005 and p< 0.03,
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respectively) fewer (9%) cells in the compact myocardium that expressed Wt1. In
addition, Wt1 expression at E13.5 was also significantly reduced in the myocardial area
of FGFR2b-/- and Fgf10-/- hearts (Supplemental Figure 4). However, Wt1 expression in
the epicardium appeared normal. To further determine whether epicardial EMT could be
impaired, expression of E-cadherin, a factor involved in epicardial EMT, was examined.
Like Wt1, E-cadherin expression appeared normal in the epicardium of Fgfr1/2Wt1-Cre and
Fgf10-/- hearts (Supplemental Figure 5).
A prediction of these observations is that activation of the epicardial FGF
signaling pathways would increase migration of EPDCs within the compact myocardium.
We therefore examined the expression of Wt1 in embryos induced to overexpress FGF10
(Figure 5E-G). Embryos containing the Rosa26-rtTA; TetO-Fgf10 alleles were induced
with doxycycline from E15.5 to E17.5 to upregulate expression of Fgf10 throughout most
embryonic tissues. Hearts from these embryos showed a 10% (p< 0.05) increase in the
number of Wt1 positive cells within the myocardium compared to wild type or
heterozygous littermate controls.
To further characterize the EPDCs within the myocardium, hearts were stained
with an antibody to vimentin, a marker of cardiac fibroblasts (Figure 5H-K). Consistent
with the decreased number of Wt1-positive cells within the myocardium of Fgfr1/2Wt1-Cre
and Fgf10-/- hearts, the number of vimentin-positive cells was also decreased in
Fgfr1/2Wt1-Cre and Fgf10-/- hearts compared to controls. These loss-of-function and gainof-function studies support a model in which FGF signaling regulates migration of a
subset of EPDCs (that will become cardiac fibroblasts) into the compact myocardium.
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FGF signaling regulates EPDC migration.
To determine whether FGF10 signaling regulates migration of EPDCs into the
myocardium, hearts were labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE) to label epicardial cells (Morabito et al., 2001), allowing their location to be
imaged following explant culture. CFSE is permeable to cells, but once inside a cell,
esterases cleave the molecule trapping it in the cytosol. To determine whether epicardial
cells could be specifically labeled, dissected E17.5 wild type hearts were treated with
CFSE for 1 hr and then fixed, sectioned and immunostained for Wt1. CFSE and Wt1
were co-localized in the epicardial cell layer, and Wt1 was also present in EPDCs that
had already migrated into the myocardium prior to labeling with CFSE (Figure 6A-C,
arrows highlight Wt1+ cells that have already migrated into the myocardium). To
determine whether FGF10 activated FGFR signaling in CFSE-labeled cells, CFSElabeled and FGF10-treated explants were stained for p-Erk, a downstream target of
activated FGFRs. Exposure to FGF10 for 48 hrs resulted in an increase in p-Erk labeling
of CSFE+ cells in the epicardium and myocardium, but not of CFSE- cells within the
compact myocardium (Figure 6D-F). This increase in p-Erk labeling in response to
FGF10 was blocked by treatment with the FGFR inhibitor PD173074.
To determine if EPDC migration into the myocardium responded to FGF10,
E17.5 heart explants were treated with CFSE for 1 hr, washed, and then cultured for 48 hr
with or without FGF10 and PD173074. In addition, to determine the specificity of FGF
signaling, explants were also treated with FGF9, a ligand that is expressed in the
epicardium that signals to cardiomyocytes (Figure 6G-K). In response to treatment with
FGF10, explants showed a significant (p< 0.002) increase in CFSE-labeled cells within
the sub-epicardial space and compact myocardium. Addition of the FGFR inhibitor,
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PD173074, along with FGF10 resulted in a significant (p< 0.005) decrease in CFSElabeled cells within the sub-epicardial space and compact myocardium, while treatment
of explants with FGF9 had no effect on migration of CFSE-labeled epicardial cells
(Figure 6K, O). Taken together, these data demonstrate that FGF10 is sufficient to
increase CFSE-labeled cell movement into the myocardium.
To determine whether FGF10 had an effect on EPDCs that had already migrated
into the myocardium prior to CFSE labeling, the number of Wt1+, CFSE- cells in FGF10treated explanted hearts were counted. Consistent with a model in which FGF10 signals
only to FGFR1b/FGFR2b in epicardial cells, there was no change in the number of Wt+,
CFSE-, EPDCs following FGF10 treatment (Figure 6L-O).

FGF10 regulates formation of cardiac fibroblasts
During heart development, epicardial cells give rise to cardiac fibroblasts and
smooth muscle cells that populate the compact myocardium. Under specialized
conditions, such as following injury, epicardial cells may also give rise to cardiomyocytes
and endothelial cells. To determine the fate of epicardial cells that respond to FGF10,
explants labeled with CFSE and treated with FGF10 for 48 hr were sectioned and
immunostained for markers of specific cardiac lineages including myocytes, endothelial
cells, smooth muscle cells and fibroblasts (Figure 7). CFSE-labeled cells did not coimmunostain with antibodies to myocytes, endothelial cells, or smooth muscle cells, but
did co-label with an antibody to vimentin, a marker expressed on fibroblasts (Figure 7DF). These data suggest that FGF10 promotes formation and movement of EPDCs that
preferentially differentiate into cardiac fibroblasts.
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To determine whether FGF signaling could affect the motility of epicardial cells,
live-imaging was used to monitor movement of isolated epicardial cells from Fgfr2b-/and wild type hearts and hearts treated with vehicle or PD173074 (Figure 8). Epicardial
cells from Fgfr2b-/- hearts showed a significantly (p< 0.02) shorter displacement, but
similar distance traveled when compared to wild type epicardial cells. Consistent with
this result, epicardial cells treated with PD173074 also showed a significantly (p< 0.001)
shorter displacement and no change in the distance traveled. Addition of FGF10 to
epicardial cell cultures did not increase epicardial cell motility (data not shown),
indicating that FGF signaling was likely saturated in these cultures.

Discussion
Epicardial derived cells give rise to several cell types that populate the compact
myocardium. These include interstitial fibroblasts, perivascular cells and smooth muscle
cells. EPDCs also regulate growth of the myocardium but the factors that regulate their
differentiation and their migration into the myocardium are poorly understood. We show
that during late embryonic development, FGF10 signals to epicardial and epicardial
derived cells through FGFR2b to induce their migration into the myocardium.
In mice conditionally lacking Fgfr1 and Fgfr2 in epicardial cells, or lacking
Fgf10, significantly fewer EPDCs were observed within the compact myocardium.
Several mechanisms could result in this phenotype including: defects in epicardial EMT;
failure of EPDCs to migrate into the compact myocardium; or increased death of EPDCs.
EMT is a complex process that requires the dissolution of cell-cell junctions, loss of
apical-basal polarity, and finally the modification of cytoskeletal proteins to a
mesenchymal phenotype that permits, in the case of epicardial cells, movement into the
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subepicardial space (reviewed in Thiery et al., 2009). Although the precise signals and
mechanisms governing epicardial EMT are not known, epicardial EMT requires βcatenin-dependent asymmetrical cell division (Wu et al., 2010) and Wt1 mediated
repression of E-cadherin and upregulation of snail (Martinez-Estrada et al., 2010). In
mice lacking FGF10 or epicardial FGFR1/2, epicardial EMT appears to occur normally,
as proliferation and Wt1, snail and β-catenin expression were not changed in epicardial
cells. Furthermore, increased apoptosis of EPDCs, which could also explain fewer of
these cells within the myocardium, is also unlikely, since staining for activated caspase 3
revealed no increase in cell death in Fgfr1r2Wt1-Cre and Fgf10-/- hearts.
Following epicardial EMT, EPDCs migrate further into the myocardium and
differentiate into either smooth muscle cells or cardiac fibroblasts. The mechanisms that
direct EPDCs into the compact myocardium are not known, however, our data suggests
that FGF10/FGFR2b signaling may regulate epicardial movement into the myocardium.
In primary epicardial cell cultures lacking Fgfr2b or treated with FGFR kinase inhibitors,
we observed a reduction in cell displacement. These results could be explained by FGF10
functioning as a chemotactic factor or regulating cell motility (displacement in epicardial
cultures). In vivo, FGF10 is unlikely to regulate directional migration of EPDCs in the
heart, because of its diffuse expression throughout the compact myocardium. In contrast,
in the lung, Fgf10 is expressed focally in mesenchyme where it functions to induce
epithelial branching and migration towards the source of FGF10 (Weaver et al., 2000). In
addition, in heart explants, addition of FGF10 protein to the media induced EPDC
migration into the compact myocardium, suggesting that focal expression of FGF10 is
not required. Recently, it was demonstrated that FGF-regulated increases in cell motility
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could have net positive effects on directional cell movements required for embryonic axis
elongation (Benazeraf et al., 2010). It is thus possible that FGF10 regulated cell motility
could account for the specific influx of cardiac fibroblasts into the compact myocardium.
Other factors like PDGFRβ and Alk5, that regulate either epicardial migration or EMT,
have been found to specifically affect vascular smooth muscle cell recruitment or
differentiation, but do not have reported effects on cardiac fibroblasts (Mellgren et al.,
2008; Sridurongrit et al., 2008). We posit that FGF preferentially regulates migration of
cardiac fibroblasts and PDGFβ preferentially regulates migration of vascular smooth
muscle cells.
FGFs often signal bidirectionally during organogenesis, for example in limb bud
and lung development (Morrisey and Hogan, 2010; Yang, 2009; Zeller et al., 2009).
During midgestation heart development, communication between the epicardium and
myocardium appears necessary to regulate the ultimate size of the heart. Although
reciprocal FGF signaling between mesenchymal and epicardial tissues is important for
heart development, other signaling molecules, direct cell-cell contact, and physiological
factors are likely to interact with FGF signaling to coordinate heart size with growth of
the embryo and its physiological requirements.
Multiple signals regulate growth of the myocardium (Sucov et al., 2009). Of
these, epicardial derived FGF9 and FGF16 are factors that directly signal to FGFRs
expressed in cardiomyocytes. Although myocardial proliferation is reduced in mice
lacking FGF9 (Lavine et al., 2005), FGF16 (Hotta et al., 2008) or lacking both FGF9 and
FGF16 (unpublished), proliferation is clearly not arrested. This indicates that other
factors must act in parallel to FGF9/16 to regulate myocardial proliferation. Other factors
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could include other growth factors such as WNT9b (Merki et al., 2005), or direct
interactions between cells. Recently, cardiac fibroblasts were shown to directly induce
myocardial proliferation through a mechanism involving HBEGF and integrin signaling
(Ieda et al., 2009). The major source of embryonic cardiac fibroblasts during
development is EPDCs. In our model, inactivation of FGF signaling in EPDCs leads to a
decrease in EPDCs that specifically give rise to cardiac fibroblasts within the compact
myocardium. Interestingly, we also observed a coincident decrease in myocardial
proliferation and a reduction in heart size. We posit that decreased myocardial
proliferation in hearts lacking epicardial FGF signaling could result from indirect
consequences of decreased numbers of interstitial cardiac fibroblasts. This is consistent
with small heart size phenotypes observed in other mutations that disrupt proepicardial
migration, defects in epicardial EMT and EPDC migration into the myocardium
(Martinez-Estrada et al., 2010; Rhee et al., 2009; Wu et al., 2010).
In the studies presented here, the Fgfr2b-/- hearts appear to have a more severe
(smaller heart) phenotype than Fgfr1/2Wt1-Cre hearts. Fgfr2b-/- is a germline knockout;
therefore deletion of Fgfr2b is complete and can act over a longer period of time
compared to a conditional knockout. In addition, other developmental defects could
indirectly contribute to the cardiac phenotype in Fgfr2b-/- hearts.
Understanding mechanisms that regulate myocardial growth have historically
been the focus of much research because of the importance of the cardiomyocyte to heart
homeostasis and response to injury. One of the challenges that have slowed advances in
the treatment of the injured heat is the limited ability of adult cardiomyocytes to
proliferate. Recent studies on epicardial cells and their ability to differentiate into various
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cell types and communicate with cardiac myocytes have suggested new therapeutic
targets to treat heart disease. Future studies are needed to determine whether
FGF10/FGFR2b signaling occurs in the adult heart under homeostatic or pathological
conditions and whether this signaling pathway could be therapeutically manipulated to
promote cardiac protection or regeneration.

Materials and Methods
Mice
Mouse lines used: Fgfr2b-/- (Revest et al., 2001), Fgf7-/- (Guo et al., 1996), Fgf10-/(Min et al., 1998), Wt1-Cre (Min et al., 1998), Fgfr1f/f (Trokovic et al., 2003), Fgfr2f/f (Yu
et al., 2003), Rosa26-rtTA (Belteki et al., 2005), TetO-Fgf10 (Clark et al., 2001).

Histology
Paraffin sections (5µm) were stained with hematoxilin and eosin (H&E) for
general visualization. Myocardial area was calculated with the contouring tool using
Canvas X software. Cross-sectional area of the heart was defined as the measure of total
muscle including both chambers in one mid-frontal section. Atrial area was not included.
In Fgfr1Wt1-Cre, Fgfr2Wt1-Cre and Fgfr1/2Wt1-Cre values were normalized to body weight by
dividing area by total body weight. Heart wall thickness was calculated with the linear
dimensioning tool in Canvas X software. Compact myocardial thickness was determined
by averaging three measurements of the length from the subepicardial layer to the edge of
the compact myocardium in histological sections from each embryo examined. Statistical
significance was determined using the student’s t-test, with n representing number of
embryonic hearts examined.
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Immunohistochemistry and Immunofluorescence
For immunohistochemistry, paraffin sections (5μm) were dewaxed, rehydrated,
incubated in methanol/hydrogen peroxide, antigen unmasked, and blocked in 10% goat
serum. Antigen unmasking was performed by incubating sections in 1% trypsin for 5 min
at room temperature or by pressure cooking in citrate buffer for 15 min. Primary
antibodies used were FGFR2 (rabbit IgG, Santa Cruz, sc-122), BrdU (mouse IgG, Becton
and Dickinson, 1:100), activated caspase 3 (BD Pharmigen cat# 557035) and Snail1 (a
gift from A. García de Herreros Madueno). Expression was visualized using the
Histostatin SP broad spectrum (DAB) kit from Invitrogen (95-9643).
Immunofluorescence was performed the same way excluding blocking endogenous
peroxidase. Primary antibodies used were Wt1 (mouse IgG1κ, Dakocytomation, M3561),
vimentin (mouse IgM, Abcam, ab20346), pERK (mouse IgG2a, Santa Cruz, sc-7383),
desmin (mouse IgG1, Research Diagnostics Inc, RDI-PRO10519), pecam (rabbit IgG,
Abcam, ab28364), smooth muscle cell actin (mouse IgG1-Cy3, Sigma, c-6198), Ecadherin (mouse IgG2a, BDTransduction, #610181), b-catenin (mouse IgG1,
BDTransduction, #610153) and troponin (mouse IgG2a, Developmental Studies
Hybridoma Bank, CT3-s). Secondary antibodies were incubated for 1hr and visualized
with a Zeiss confocal microscope or Zeiss apotome microscope.
Staining for β-galactosidase was performed as described (Soriano, 1999).

In Situ Hybridization
Tissues were fixed in 4% formaldehyde, embedded in paraffin and sectioned (5
μm). In situ hybridization was performed as previously described (Wilkinson, 1992). The
Fgf10 in situ probe was provided by B. Hogan (Bellusci et al., 1997).
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Proliferation Analysis
For embryos, pregnant females at E15.5 and E17.5 were injected IP with BrdU
(50 μg/g body weight), 30 minutes prior to sacrifice. BrdU immunohistochemistry was
performed as described above. Sections were counterstained with hematoxylin. For
statistical analysis, two areas from three different specimens were analyzed per stage. The
number of BrdU-positive nuclei relative to the total number of nuclei was counted from
two 63x fields per section. Data is shown as mean ± SD.
For organ cultures, 6.4 ng/ml BrdU was added to the culture media 30 min prior
to fixation. BrdU incorporation was detected by immunohistochemistry. After fixation,
tissues were embeded in paraffin and sectioned. Immunohistochemistry was performed as
described above.

Heart explant culture
Hearts were dissected under aseptic conditions at E17.5. Hearts were then labeled
with 50mM CFSE (5-(and-6)-carboxy-2’,7’-dichlorofluorescein diacetate succinimidyl
ester, Invitrogen, cat# C1165) for one hour and placed in glass scintillation vials
containing 1 ml of media (DMEM, 2 µg/ml Heparin, antibiotic and antimycotic). Vehicle
(0.25 μl/ml DMSO), FGF10 (10 nM, Peprotech Inc.), FGF9 (10 nM, Peprotech Inc.) or
PD173074 (25 nM, Pfizer Inc.) was added to the vials. Vials were incubated for 48 h on a
rocker at 37°C/5% CO2 with loose caps. Hearts were harvested, fixed in 10% formalin or
4% formaldehide and embeded in paraffin prior to sectioning.

Epicardial live imaging
Hearts were dissected under aseptic conditions at E15.5 and set in 1% collagen
coated delta T dishes (Fisher) over night in 350 µl of media (DMEM, 5% horse serum, 2
µg/ml Heparin and antibiotic and antimycotic). Hearts were then removed from the dish
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leaving foci of epicardial cells attached to the dish. Adherent cells were washed and 2 ml
of media was added to the cultures. FGF inhibitor (PD173074, 22 nM) was added as
indicated. Cultures were placed in a live imaging chamber on Leica DMI 6000B
microscope and maintained at 37°C in 5% CO2. 20x images were taken every 10 min for
a period of 24 h. Image series were taken with a camera Retiga Exi. Images were
prepared and exported using the CIMAT software (C. Little, UMKC, Kansas City)
.Images were analyzed using the Manual Tracking plugin for Image J software. X and Y
coordinates and scaling were used to calculate the distance, displacement, speed and
velocity of cells in culture.
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Figures and Figure Legends

Figure 1.
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Figure 1.
Fgfr2b and Fgf10 regulate heart size. (A-D, A’-D’) H&E staining of hearts at
E17.5. Control (A,A’), Fgfr2b-/- (B,B’), Fgf7-/- (C,C’) and Fgf10-/- (D,D’). Dashed
rectangle in (A-D) denotes magnified area in (A’-D’). (E) Quantification of the relative
area of the heart. Control, n=8; Fgfr2b-/-, n=8, ** p<0.001; Fgf10-/-, n=8, * p<0.02; Fgf7-/, n=5. (F) Quantification of left ventricular wall thickness (red line in A’-D’). Fgfr2b-/-,
n=6, *p<0.02; Fgf10-/-, n=9, * p<0.003; Fgf7-/-, n=5. (G,H) Short axis in utero
echocardiogram at E17.5 of control (G) and Fgfr2b-/- heart (H). Area measured (dashed
white lines) and wall thickness measured (yellow lines) are placed at end diastole
according to the movie shown in supplemental Figure 1. LV (left ventricle); S (septum);
RV (right ventricle). (I-K) Quantification of left ventricular posterior wall diameter at end
diastole (LVPWd), n=7, ** p<0.0003; right ventricular posterior wall diameter at end
diastole (RVPWd), n=7, *p<0.02; interventricular septum diameter at end diastole, n=7,
** p<0.001. Scale bar: (A-D) 500µm, (A’-D’) 100µm. Control hearts are a mix of wild
type, Fgfr2b+/- and Fgf7+/-, Fgf10+/-. Asterisk indicates statistically significant difference
compared with controls.
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Figure 2.
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Figure 2.
Expression of Fgfr2b and Fgf10 in the left ventricle of the heart at E17.5. (A-B)
Fgf10 in situ hybridization showing Fgf10 mRNA in cells within the myocardial area in
controls, no expression of FGF10 was observed in Fgf10-/- hearts. (C-D)
Immunohistochemistry showing expression of FGFR2 throughout the heart in controls
(C). In Fgfr2b-/- heart (D), FGFR2b is absent from the epicardial layer. Dashed lines
denotes border between myocardial and epicardial layer. Scale bar: 20 µm.
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Figure 3.
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Figure 3.
Decreased heart size after epicardial conditional inactivation of Fgfr1 and Fgfr2
with Wt1-Cre. (A-D, A’-D’) H&E staining of E17.5 control (A,A’), Fgfr1Wt1-Cre (B,B’),
Fgfr2Wt1-Cre (C,C’), and Fgfr1/2Wt1-Cre (D,D’) hearts. Fgfr1/2Wt1-Cre hearts are smaller
compared to controls and display a thinner compact myocardium. Dashed rectangle in
(A-D) denotes magnified area in (A’-D’). (E) Quantification of the left ventricle wall
thickness (red line in A’-D’). Control, n=14; Fgfr1Wt1-Cre, n=5; Fgfr2 Wt1-Cre, n=10;
Fgfr1/2Wt1-Cre, n=9, ** p<0.001. Scale bar: (A-D) 500µm, (A’-D’) 100µm. (F)
Quantification of heart cross-sectional area normalized to body weight. Fgfr1/2Wt1-Cre,
n=10, p<0.003; Fgfr1Wt1-Cre, n=5; Fgfr2Wt1-Cre, n=9. Control hearts contain Wt1-Cre and
are a combination of wild type and floxed alleles of Fgfr1 and Fgfr2. Asterisk indicates
statistically significant difference compared with controls.
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Figure 4.
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Figure 4.
Reduced myocardial, but not epicardial, proliferation in Fgfr1/2Wt1-Cre heart. (AB) BrdU incorporation at E15.5. (A’-B’) BrdU incorporation at E17.5. (C) Quantification
of the percent of BrdU positive cells within the myocardium, showing decreased
proliferation with age and decreased proliferation in Fgfr1/2Wt1-Cre hearts compared to
control hearts. E15.5, n=3, * p<0.04; E17.5, n=5, * p<0.03. (D) Quantification of the
percent of BrdU positive cells within the epicardium showing no difference between
controls and Fgfr1/2Wt1-Cre hearts. Scale bar: 20µm.
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Figure 5.
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Figure 5.
FGF signaling to epicardial cells regulates migration of EPDCs into the
myocardium. (A-C) Wt1 immunofluorescence at E17.5 showing fewer Wt1+ cells within
the myocardium of Fgfr1/2Wt1-Cre (B) and Fgf10-/- (C) hearts. Wt1, red; DAPI, blue. (D)
Quantification of the percent of Wt1+ cells in the myocardium. Fgfr1/2Wt1-Cre, n=4, *
p<0.005, Fgf10-/-, n=7, * p< 0.03. (E-F) Wt1 immunofluorescence at E17.5 of control (E)
and Rosa26-rtTA;TetO-Fgf10 (F) induced with doxycycline from E15.5 to E17.5. (G)
Quantification of the percentage of Wt1+ cells in the myocardium. n=5, * p<0.05. (H-K)
Vimentin immunofluorescence at E17.5 showing fewer vimentin+ cells within the
myocardium of Fgfr1/2Wt1-Cre (I) and Fgf10-/- (J) hearts. Vimentin, green; DAPI, blue. (K)
Quantification of the percent of Vimentin+ cells in the myocardium. Fgfr1/2Wt1-Cre, n=8, *
p<0.005; Fgf10-/-, n=10, * p< 0.02. Scale bar in F, I, M, 20μm. White (x) denotes red
blood cells and dashed white line denotes the epicardial boundary.
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Figure 6.
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Figure 6.
Fgf10 induces migration of EPDCs in explant culture. (A-C) Hearts explanted at
E17.5 and treated with CFSE for 1 h labels only epicardial cells (A) and not EPDCs that
have already migrated into the myocardium (B,C). (D-F) pErk immunohistochemistry of
CFSE-labeled explanted hearts treated with FGF10 (E) and FGF10 plus PD173074 (F)
for 48 h. Arrows indicates cells positive for pErk and CFSE. (G-J, G’-J’) Migration of
CFSE-labeled epicardial cells into the myocardium following treatment with FGF9,
(H,H’); FGF10, (I,I’); and FGF10 plus PD173074, (J,J’). CFSE, green; desmin, red (to
identify the boundary between myocardium and epicardium), DAPI, blue. (K)
Quantification of number of CFSE+ within the myocardium after 48 h in culture. +FGF9,
n=8; +FGF10, n=19, * p<0.003, significant increase compared to control; +FGF10,
+PD173074, n=10, * p<0.006, significant decrease compared to control.
(L-N) FGF10-induced CFSE-labeled EPDCs in the myocardium are positive for
Wt1. Explanted hearts labeled with CFSE were treated with FGF10 (M) or FGF10 plus
PD173074 (N) for 48 h and then sectioned and immunostained for Wt1. CFSE, green;
Wt1, red. (O) Quantification of the number of Wt1+ cells within the myocardium. FGF10
treatment significantly increased the number of CFSE+,Wt1+ double positive cells within
the myocardium, n=10, * p<0.002; but did not affect the number of pre-existing (CSFE-)
Wt1+ within the myocardium. Treatment with FGF10 and PD173074 significantly
decreased the number of CFSE-,Wt1+ cells within the myocardium, n=10, * p<0.004 and
the number of CFSE+,Wt1+ within the myocardium, n=10, * p<0.002. Scale bar: (A-B),
100µm (D-F, G-J, L-N) 20µm
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Figure 7.
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Figure 7.
Migratory EPDCs become cardiac fibroblasts. Explanted hearts were labeled with
CFSE and treated with FGF10. After 24 h, hearts were sectioned and stained with
markers for (A) cardiac muscle, troponin (red); (B) smooth muscle actin, acta2 (red); (C)
endothelial cells, pecam (red); and (D-F) fibroblasts, vimentin (red). (D’-F’) CFSE is
only co-expressed with vimentin. Scale bar: 20µm. Dashed squared denotes the
magnified insert (D’-F’)
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Figure 8.
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Figure 8.
FGF signaling regulates displacement of epicardial cells in culture. (A-D)
Representative cells and cell paths during the 24 h culture period. (E) Quantification of
cell displacement over 24 h. (F) Quantification of distance of distance traveled over 24 h.
Net movement (displacement) of (A’) wildtype and (C’) vehicle treated cells is greater
than that of Fgfr2b-/- cells, n=79, * p<0.02; and cells treated with PD173074, n=77, **
p<0.001. Scale bar: 20µm.
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Supplemental figure 1.
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Supplemental figure 1.
Coronary vasculature in E17.5 hearts. Immunostaining for PECAM/CD31 (red) in
control, Fgf10-/- and Fgfr1/2Wt1-Cre hearts. (A) Control , (B) Fgf10-/-, and (C) Fgfr1/2Wt1Cre

. Compared to controls, the vascular plexus in Fgfr1/2Wt1-Cre and Fgf10-/- hearts appears

normal. Scale bar: 10µm. Dashed lines contours the epicardial layer.
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Supplemental figure 2.
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Supplemental figure 2.
Assay for cell death in E17.5 hearts. Immunostaining for activated caspase 3 in
control, Fgf10-/- and Fgfr1/2Wt1-Cre hearts. (A) Control, (B) Fgf10-/-, and (C) Fgfr1/2Wt1-Cre.
No change in capase 3 staining was observed. Scale bar: 20µm.
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Supplemental figure 3.
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Supplemental figure 3.
Identification of EPDCs within the myocardium at E13.5. (A-C) Immunostaining
for Wt1 (red) showing fewer Wt1+ cells within the myocardium in Fgfr2b-/- (B) and
Fgf10-/- (C) hearts, compared to control (A) hearts. (D) Quantification of Wt1+ cells
located within the myocardium. Control, n=5; Fgfr2b-/-, n=4, * p< 0.001; Fgf10-/-, n=3 **
p<0.01. DAPI, blue. White line denotes the boundary between epicardium and
myocardium and white arrows indicate Wt1+ cells within the myocardium. Scale bar:
20µm.
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Supplemental figure 4.
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Supplemental figure 4.
EMT is not impaired in Fgfr1/2Wt1-Cre hearts. Immunostaining for E-cadherin
(green) and β-catenin (red) at E17.5 in control (A) and Fgfr1/2Wt1-Cre hearts (B). Arrows
indicate points of adhesion of epicardial cells were both E-cadherin and β-catenin are
normally co-expressed. Immunostaining for Snail1 at E15.5 (bottom) shows normal
expression in the epicardial cell layer of control and Fgfr1/2Wt1-Cre hearts. Dashed line
contours the epicardial layer. Scale bar: 10μm.
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Chapter 3
Future Directions

Summary
In this thesis I explored the role of FGF signaling during development of
epicardial-derived cells (EPDCs). I found that FGF10, secreted from the
myocardium, signals to FGFR2b in the epicardium to activate migration of epicardial
cells into the myocardium. Epicardial derived cells populate the heart with vascular
smooth muscle cells (vsmc) and cardiac fibroblasts (Mikawa and Gourdie, 1996;
Vrancken Peeters et al., 1999). These cell types are needed in the heart to complete
the formation of the vascular tree and the fibrous skeleton. I observed that FGF10
specifically signaled to cardiac fibroblasts but not to vsmc to induce their migration
into the myocardium. In addition, inactivation of FGF10/FGFR2b/ signaling in
mouse embryos resulted in a smaller heart visible by embryonic day 17.5 (E17.5). It
has been shown that cardiac fibroblasts are important for cardiac myocyte
proliferation during late gestation (Ieda et al., 2009). The largest contributors of
cardiac fibroblasts during development are epicardial-derived cells (Krenning et al.,
2010). Therefore, defective migration of cardiac fibroblasts could result in a
decreased number of cardiac fibroblast within the myocardium, impeding their
interaction with myocytes. In turn, decreased interaction affects proliferation, leading
to the formation of a smaller heart. Taking this into account, we hypothesize that
when the FGF10/FGFR2b/ signaling is disrupted we observe a decrease in heart size
due to the decrease in cardiac fibroblast migration and subsequent signaling to the
cardiomyocyte.
These observations contribute to the knowledge we have about epicardial
cells. Epicardial cells are important for development and because of their potential to
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serve as a progenitor cell during cardiac injury. Because developmental pathways
normally required for the formation of epicardial and epicardial-derived cells may be
necessary for homeostasis and reactivation of the epicardium in the adult, it remains
important to learn how to manipulate this cell type in the adult context (Gittenbergerde Groot et al., 2010; Limana et al., 2010; Shrivastava et al., 2010; Wessels and
Perez-Pomares, 2004). Therefore, FGF10 could potentially be an important factor
during heart repair, and future studies are necessary to determine if this is so. Next I
am going to present various questions that stem from the research done for this thesis
and discuss potential directions we can take to investigate them.
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Involvement of FGF7 in epicardial development.
Fgfr2b-/- hearts have a thinner compact myocardium. FGFR2b is expressed in
the epicardium, therefore we hypothesized that members of the FGF7 subfamily
could potentially signal to FGFR2b. To examine this possibility, we performed rtPCR of whole wildtype hearts at E17.5. From the members of the FGF7 subfamily of
ligands, we detected Fgf10 and Fgf7 mRNA expression but not of Fgf3 or Fgf22
(data not shown). We next examined the overall phenotype of both Fgf10-/- and
FgF7-/-hearts. We found that Fgf7-/- by itself does not develop a smaller heart, but
Fgf10-/- does, suggesting that FGF10 is the main ligand for FGFR2b in the
epicardium. We also were able to generate two Fgf7-/- and Fgf10-/- double germline
knockouts which yielded an even smaller heart compared to the Fgf10-/- (Figure 1).
A simple way to explain the differences in the phenotypes of Fgf7-/-, Fgf10-/- and the
Fgf7-/-, Fgf10-/-, double knockout could be that FGF7 and FGF10 pathways are
redundant, which leads to a more severe phenotype when both are absent in the
double knockout. The differences in the severity of the phenotype of the individual
knockouts could be explained by the different binding specificities of FGF7 and
FGF10 to FGFR2b in the heart. Binding of FGF ligands to their receptors are
regulated by heparan sulfate proteoglycans (HSP). HSP epitopes are found to be
expressed in a tissue-specific and developmentally regulated fashion (Mohammadi et
al., 2005). It is possible that FGF10, but not FGF7, is favored to bind FGFR2b due to
the specific HSP present. In this scenario, FGF7 could still bind FGFR2b but not
predominantly, yielding a very week phenotype when deleted on its own. When
deleted along with FGF10, the phenotype becomes more severe.
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In the future, we need to generate more Fgf7 and Fgf10 double knockouts to
characterize their phenotype and investigate the extent to which Fgf7 is necessary in
the epicardium for migration of the epicardial cells. It is also possible that deletion of
Fgf7 along with Fgf10 could uncover other functions of FGF in the development of
epicardial cells, such as differentiation and EMT that might require a combination of
both ligands.
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Initiation and promotion of epicardial cell migration by FGF10
In studies performed for this thesis, we found that fewer epicardial-derived
cells, specifically EPDCs that differentiated into cardiac fibroblasts, had migrated
into the myocardium of Fgfr1/r2 Wt1-Cre and Fgf10-/- hearts by late gestational stages.
In addition, we found that addition of FGF10 to explanted hearts could induce
migration of labeled epicardial cells into the myocardium. We interpreted that these
results could reflect either abnormal EMT or migration. We were unable to find
evidence that EMT was defective in our embryonic mouse models. Instead, we
observed that wild type isolated epicardial cells move longer net distances than
Fgfr2b-/- epicardial cells and epicardial cells treated with an FGFR inhibitor. This
observation suggests that FGF10 can signal to epicardial cells within the epicardial
layer. It is still unclear if FGF10 acts as a competence factor to potentiate epicardial
cells to begin migration or if it acts as a signal that is required to direct or promote
motility during the course of migration. It has been established that FGF10 signals to
FGFR2b and that when EMT occurs there is a shift in expression from FGFR2b to
FGFR2c (Savagner et al., 1994). If epicardial cells shifted expression of FGFR2b to
FGFR2c during EMT, FGF10 could only continue signaling to the EPDCs for as long
as they retained FGFR2b on their cell surface. In other words, can FGF10 signal to
epicardial cells and/or the delaminated EPDCs? The simplest way to examine this
possibility is to determine the dynamic domains of expression of Fgfr2b and Fgfr2c
in the heart. Unfortunately, no antibody has been developed to specifically detect
each isoform. One way is to use a general FGFR2 antibody on tissue from individual
isoform knockouts. Using this method, one can delineate the expression of FGFR2
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by absence of staining in each specific isoform knockout. Another way to investigate
if FGF10 could functionally signal to EPDCs is to isolate epicardial-derived cells.
We know that epicardial-derived cells continue expressing the marker Wt1 as they
migrate into the myocardium; therefore, cells that are express Wt1 could either be
epicardial cells or EPDCs (Perez-Pomares et al., 2002; Rhee et al., 2009 ). We also
know that an adhesion molecule important for long-term attachment of epicardial
cells is α4β1 integrin; this means that epicardial cells, but not EPDCs, will be
positive for both α4β1 and Wt1 (Sengbusch et al., 2002). We could use cell sorting to
isolate epicardial-derived cells based on their being immunopositive for Wt1 and
immunonegative for α4β1 integrin (Wt1+; α4β1-). Isolated EPDCs from Fgf10-/- and
wild type hearts can be cultured and visualized using live imaging to calculate the
net displacement and distance of their movement in the presence of FGF10 protein.
also, look at ability of different FGF ligands to bind to the cell surfeace (iodinated or
fluorescent tagged)
Whether FGF10 is able to signal to EPDCs as they migrate is important in
investigating how it elicits that migration. FGF10 could promote migration in various
ways. FGF10 could act as a chemotactic molecule. It has been shown that FGF10 can
act as a chemotactic factor for distal lung epithelia; therefore, it is possible that it
could act in the same way in the heart (Bellusci et al., 1997; Park et al., 1998). Also
FGF10 could create a gradient of random cell motility without directionality that
could result in global directed movement (Benazeraf et al., 2010). In addition FGF10
could signal to the EPDC to maintain establishment of the polarized lamellipodia.
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In our experiments FGF10 does not appear to be acting as a chemotactic
factor. In the lung, were FGF signaling is chemotactic, the expression of FGF10 is
focally located in the mesenchyme. This ensures proper directionality for the
migration of lung distal epithelium. In contrast, in the heart the expression of FGF10
appears to be spread throughout the compact myocardium but not focally located. In
addition, induction of heart explants with FGF10 added to the media; resulted in an
increased migration of cells into the myocardium when compared with controls.
These data do not support a chemotactic role for FGF10 in the heart. Nonetheless, w e
have designed experiments to examine directionality of EPDCs. We can isolate
epicardial cells in colonies, embed them in soft agar, and place a FGF10-coated bead
in the vicinity of the colony of cells. In the future, we will investigate whether cells
within these colonies move towards the bead coated with FGF10 or not. We will also
try isolating colonies of cells from Fgfr2b-/- hearts and treat wild type colonies with
FGFR inhibitor.
Our live imaging experiments showed that cells from wildtype, Fgfr2b-/- and
control cells treated with FGFR inhibitor could all move similar distances,
suggesting that motility was not impaired by inactivation of FGF signaling in
epicardial cells. In contrast, only wild type cells treated with vehicle were able to
show the longest net displacement. This observation implies that Fgfr2b-/- cells and
wildtype cells treated with inhibitor are able to move as much as controls but that
their movement is not organized to reach a migratory endpoint. In this experiment
wildtype epicardial cells did not move in the same direction but were able to move
successfully from one point to another. In contrast, Fgfr2b-/- cells and wildtype cells
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treated with inhibitor were not able to move from one point to another, instead they
remained in the same area. This observation suggests that FGF10 may function to
create a gradient of random cell motility without directionality that can result in
global directed movement.
Interestingly, in the live imaging movies, we observed that wildtype cell were
able to maintained a polarized lamellipodia, but, Fgfr2b-/- cells and wildtype cells
treated with inhibitor did not. This observation suggests that FGF10 could control
migration of EPDCs by the maintenance of a polarized lamellipodia independent
from directionality. In the future we could investigate this possibility by looking at
the actin filament organization of Fgfr2b-/- and wildtype cells treated with inhibitor
during live imaging. In addition we could treat cells with an inhibitor of actin
filament motor function like blebbistatin (Benazeraf et al., 2010) to observe if it has
a similar effect to inactivation of FGF signaling.
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FGF signaling restriction to epicardial-derived cardiac myocytes.
In our study, we found that the FGF10/FGR2b signaling activates only
EPDCs that will become cardiac fibroblast, not vsmc, cardiomyocytes or endothelial
cells. Consistent with this observation, we found a decrease in cardiac fibroblasts
within the myocardium of Fgfr1/r2Wt1-Cre and Fgf10-/- hearts. This is the first time a
signal has been identified that specifically targets cardiac fibroblasts versus other
epicardial-derived cells. In the past, other researchers have reported that PDGFRβ, βcatenin, Alk5 and Wt1, amongst other genes, are involved in either migration or
EMT of epicardial-derived cells that specifically develop into vascular smooth
muscle cells (Martinez-Estrada et al., 2010; Mellgren et al., 2008; Sridurongrit et al.,
2008; Zamora et al., 2007). Mouse models from these genes present two very distinct
phenotypes of defective EPDC development: poor formation of the coronary
vasculature due to decreased recruitment or differentiation of vsmcs and thinned
compact myocardium. In contrast, Fgfr1/r2Wt1-Cre and Fgf10-/- hearts do not display
problems in the recruitment of vsmc in view of the properly formed vascular plexus.
Future experiments will concentrate on studying how the FGF signal is restricted to
only cardiac fibroblasts. Possible mechanisms of specificity could entail a balance
between PDGFβ signaling and FGF signaling. For example, epicardial cells could
receive both signals but only able to interpret and respond to one. In this case , many
other genes could be involved in making the epicardial cell competent to receive or
suppress one or the other signal. Other genes like Sprouty or Cbl which modulate
downstream pathways or recycling of receptor tyrosine kinases (RTKs) could also
play a role (Aranda et al., 2008; Miyake et al., 1999). Another plausible mechanism
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is timing, for example PDGFβ signaling could occur prior or after FGF signals to
epicardial cells. Alternatively, all epicardial cells may be fated to become vsmc, but
activation of FGF10/FGFR2b signaling results in differentiation into cardiac
fibroblasts, or vise versa.
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Indirect induction of cardiomyocyte proliferation through the cardiac fibroblast
Our study provides evidence that migration of cardiac fibroblast into the
myocardium plays a role in cardiomyocyte proliferation. We observed a decrease in
proliferation of cells within the myocardium in Fgfr1/r2 Wt1-Cre and Fgf10-/- hearts that
result in a smaller heart, visible at late gestation. There are a couple of ways that
FGF10/FGFR2b signaling could regulate proliferation. One is by signaling to the
FGF9/FGFR1c/FGFR2c pathway during midgestation or by inducing other factors
made in the epicardium. Another possible way is by inducing migration of cardiac
fibroblast during ventricular compaction (Ieda et al., 2009; Lavine et al., 2005). The
FGF9/FGFR1c/FGFR2c pathway has been established as the main mechanism for
cardiac myocyte expansion after heart looping and throughout midgestation. In this
pathway, retinoic acid receptor promotes expression of FGF9 and FGF16 in the
epicardium and endocardium. FGF9 and FGF16 signal to FGFR1c and FGFR2c in
the myocardium to directly activate proliferation and inhibit differentiation. This
pathway indirectly induces SHH expression in the epicardium which results in the
activation of VEGF and ANG2. VEGF and ANG2 promote formation of the vascular
plexus. Originally we thought that FGF10 signaling to FGFR2b might function in a
reciprocal feedback loop with FGF9/FGFR1c/FGFR2c to ensure sustained signaling
to cardiomyocytes and induction of SHH during midgestation. When we examined
development of the primitive vascular plexus, we found no delay in its formation.
We hypothesized that if the reciprocal signal was abrogated in Fgfr1/r2Wt1-Cre and
Fgf10-/- hearts we would see changes in the expression of FGF9. In the future, we
need to examine the expression of FGF9 in these mouse models to find out if FGF9
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is regulated. Correspondingly, we did not observe any changes in heart size in
Fgfr1/r2Wt1-Cre and Fgf10-/- embryos at midgestation when the
FGF9/FGFR1c/FGFR2c signaling is active. Instead, we observed changes in heart
size at late gestation starting at E17.5 coincident with the time of ventricular
compaction. Our proliferation analysis revealed that proliferation was decreased at
E15.5 and E17.5 in Fgfr1/r2Wt1-Cre and Fgf10 -/- hearts. Taken together, these data
suggest that FGF10/FGFR2b signaling pathways do not have a function along with
the mechanism of cardiomyocyte proliferation during midgestation. The data points
to a function of FGF10/FGFR2b in the later stages of cardiomyocyte expansion.
Recently it has been acknowledged that embryonic cardiac fibroblasts are
important to promote β1-integrin activated-proliferation of cardiac myocytes by
secretion of HBEGF. β1-integrin can induce activation of PI3k/Akt and
MEK/ERK1/2 in cardiomyocytes and promote cell division. This has been regarded
as the mechanism of heart growth during endpoint heart development. The main
source of embryonic cardiac fibroblasts is thought to arise from the epicardial derived cell. Other studies also have implicated not only differentiated cardiac
myocytes but also EPDCs as a cell type that can physically interact with cardiac
myocytes to induce cell proliferation, cellular alignment and contraction (Eid et al.,
1992; Weeke-Klimp et al., 2010) .
We hypothesize that in the absence of proper EPDC migration, fewer
epicardial-derived fibroblasts are going to invade the myocardium. This will result in
a decrease of β1-integrin- activated cardiomyocyte proliferation and lead to the
formation of a smaller heart. The phenotype of the Fgfr1/r2Wt1-Cre and Fgf10-/- is
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consistent with this hypothesis. In Fgfr1/r2 Wt1-Cre and Fgf10-/- hearts, we observed a
decrease in the migration of cardiac fibroblasts. Furthermore, we observed decreased
proliferation of cardiac myocytes. We hypothesize that as a result of decreased
epicardial-derived fibroblasts, migration β1-integrin signaling in the cardiac
myocytes of Fgfr1/r2 Wt1-Cre and Fgf10-/- hearts is impaired. In the future, we need to
explore this hypothesis. The downstream pathways controlling β1-integrin cell
division are PI3k/Akt and MEK/Erk1/2. A simple way to evaluate the activation of
these downstream pathways is to compare the expression of Akt and/or Erk1/2 in
Fgfr1/r2Wt1-Cre and Fgf10-/- hearts with controls. A more functional approach would
be to co-culture isolated cardiac fibroblasts from Fgfr1/r2Wt1-Cre, Fgf10-/- and controls
with isolated cardiac myocytes and ask whether proliferation of cardiomyocytes is
decreased in the mouse models. It is already known that increased titration of
isolated embryonic cardiac fibroblasts in co-cultures with myocytes increases
proliferation of cardiac myocytes; therefore, we will only see a difference using this
approach if we originally isolate fewer cardiac fibroblasts from Fgfr1/r2Wt1-Cre and
Fgf10-/- compared to control hearts. On the other hand, if we isolate similar amounts
of cardiac fibroblast from Fgfr1/r2 Wt1-Cre, Fgf10-/- and controls and see no difference
in proliferation, it could mean that cardiac fibroblasts from Fgfr1/r2Wt1-Cre and Fgf10/-

are unable to signal. In this case, we could look at the ability of these cells to

induce β1-integrin-activated proliferation through the growth factor HBEGF. We
also could explore the ability of the cardiac myocytes to produce Fibronectin1 and
Collagen 3, two ECM proteins known to bind β1-integrin to induce cardiomyocyte
proliferation.
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FGF10/FGFR2b in adult heart repair
The study of heart repair is important for the development of therapies that
could help treat heart disease, one of the most prevalent causes of mortality
worldwide. One important area of investigation is the repair of damaged tissue due to
myocardial infarction. Competent cardiac healing requires the proliferation of
myocytes, formation of new vessels and regulation of vascular remodeling. One of
the approaches taken in the past is reperfusion with known cardioprotective and
angiogenic factors like VEGF and FGF2 (Molin and Post, 2007). The expectation is
that these cardioprotective molecules will cause proliferation of cardiomyocytes,
vascularization and reduction of the fibrotic response. Although these approaches
have been successful in isolated ischemic heart models and transgenic mouse models,
they have been disappointing in clinical trials (Ludman et al., 2010). Failure of these
approaches seems to stem from the quantity and sustainability of the growth factor
and the targeting and delivery of the cells.
Another approach undertaken in the field is the use of cardiac progenitor
cells. These cells are typically grafted into the injured heart with the expectation that
it will divide and generate progeny to supply the healing myocardium (Di Nardo et
al., 2010). If developed properly, this method could overcome the targeting and
dosage problems found with angiogenic therapies, but it could be challenging to
bypass the surveillance of the immune system for rejection. In the past, several stem
cell types have been studied, such as the cardiac progenitor cell and the
mesenchymal stem cells, with some success of protection to the injured mouse and
rat heart. (Christoforou et al., 2010; Jin et al., 2009; Yi et al., 2009).
105

Recently this approach has been used to study the effects of epicardial cells in
the injured heart. Epicardial cells are considered to be undifferentiated cardiac
progenitor cells (Wessels and Perez-Pomares, 2004). These cells have been found to
differentiate into vascular smooth muscle cells, interstitial fibroblasts and
cardiomyocytes, although the latter is still controversial. Recently a study isolated
epicardial cells from adult human hearts, labeled them and injected into a mouse
heart (myocardial infarct) MI model. This injection resulted in increased
vascularization, cardiac function and decreased remodeling, suggesting that adult
epicardial cells are able to promote cardiac protection (Winter et al., 2007). In this
study, epicardial cells did not differentiate into cardiomyocytes, but engrafted rapidly
in the heart suggesting that factors secreted by the epicardial cells could be important
for cardioprotection. Additionally, Thymosin β4 has been shown to promote
epicardial cell migration that results in differentiation to vsmc and endothelial cells
in the adult mouse MI models (Smart et al., 2010).
In our studies, we observed that FGF10/FGFR2b signaling can induce
migration of epicardial cells in vivo and in vitro. In the future, it would be important
to investigate whether administration of FGF10 in the adult injured mouse heart c an
elicit similar cardioprotective effects to Thymosin β4. Many experiments could be
designed to examine the role of FGF10 in repair. First, it would be important to see if
FGF10 can elicit migration of adult epicardial cells in pathological and
pathophysiological conditions. We could generate adult mice bearing GFP-labeled
epicardial cells by crossing Gata5Cre with a R26R-EGFP reporter mouse. FGF10
could be administered either locally or systemically, and epicardial cells of Gata5106

EGFP hearts could be monitored for migration and differentiation. In parallel, we
could use FGF10-inducible mice (Rosa26-rtTA, TetO-Fgf10) to promote FGF10
expression in the adult. To follow epicardial cells, we could inject very low doses of
CFSE into the pericardium of the heart. If migration of adult epicardial cells was
successfully activated using any of these two approaches, we would expect to see an
increase in cardiac myocyte proliferation. We also expect FGF10 to promote
epicardial cell migration; specifically of cardiac fibroblasts, but not vsmc or
endothelial cells. The effects of treatment with FGF10 could differ from Thymosin
β4. Thymosin β4 is known to induce vascularization but not proliferation of
cardiomyocytes. Next we could repeat the same experiments using the adult MI
model heart to uncover the response of epicardial cells to FGF10 during repair.
If adult epicardial cells are unable to respond to FGF10 we could examine the role of
embryonic epicardial cell grafts pre-treated with FGF10 in the adult. For these
experiments, we could isolate embryonic epicardial cells, label them with CFSE and
treat them with FGF10. We can inject labeled-induced cells into adult infarcted
mouse hearts and monitor the role of these cells in myocardial repair.
In summary, FGF10 signaling to FGFR2b in epicardial cells is one of the first
signaling pathways found to be required for epicardial cell migration. It is very
important to examine and study the potential of this pathway to indirectly affect
myocyte proliferation. Understanding of this pathway and the pathways it interacts
with will aid in formulating a more comprehensive view of heart development.
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Figures and Figure Legends
Figure 1.
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Figure 1.
H&E staining of double knockout of FGF7-/- ; FGF10-/-. (A) H&E of control. (B)
H&E of Fgf10-/- . (C) H&E of FGF7-/- ; FGF10 -/-.
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Appendix A
Role of TGFβ in coronary vascular formation
Mónica Vega Hernández, David M. Ornitz

Abstract

We have shown that initiation of vessel tube formation during
coronary vascular development requires the expression of VEGF ligands and
receptors. We know that induction of VEGF expression is regulated by a
FGF9/FGFR1c/FGFR2c pathway that leads to the indirect activation of SHH.
In turn, SHH induces expression of VEGF through Patched 1 activation in the
myocardium. Here we explore alternative mechanisms of VEGF activation. In
Fgfr1/r2Mlc2v-Cre embryos, coronary artery formation is only delayed,
therefore, we hypothesized that other RTKs could be part of the normal
VEGF activation and that these elicit a compensatory mechanism observed in
the Fgfr1/r2Mlc2v-Cre mouse model. Alternatively we hypothesized that other
transcription factors could directly regulate expression of VEGF independent
from SHH signaling. In this study we look at TGFβ signaling as a candidate
pathway to induce VEGF expression during coronary vascular formation.
TGFβ signaling could act in a compensatory mechanism by inducing SHH in
a synergistic manner with FGF. Alternatively TGFβ could directly regulate
expression of VEGF. We failed to find evidence that would implicate TGFβ
signaling as important to regulate VEGF expression and in turn vascular
formation.
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Introduction

One of four Americans suffers from some sort of heart disease. Elucidating
the different molecular cascades which interplay to form the cardiovascular system
can lead to a better understanding of adult heart injury and healing. FGF’s, SHH,
VEGF’s and TGFβ’s are molecules that have been shown or proposed to be
important in myocardial proliferation and vasculogenesis. In this investigation we
evaluate the possibility that TGFβ could act downstream or synergistically during
FGF induced coronary vascular formation. We also look at the role of TGFβ in
coronary vascular development by deleting Tgfβr2 in the myocardium.

The Transforming Growth Factor Beta Super Family can be divided in two
sub groups, the Activin receptor response members and the Bone Morphogenetic
Protein (BMP) receptor response members (Moustakas and Heldin, 2009). Secreted
ligands from both groups signal through distinctive type I (signal transducing) and
type II (ligand binding) serine/threonine receptor complexes (Mokrosinski and
Krajewska, 2008). This signal is transduced intracellularly by the Smad family of
transcription factors. Smads are classified as, receptor regulated Smads (R-Smads),
common mediator Smad (Co-Smad) and Inhibitor Smad (I-Smads). The R-Smads are
activated through the receptor, consequently heterodimerizes with Co-Smad and
enter the nucleus where they can form transcriptional complexes (Miyazawa et al.,
2002).
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TGFβ super family has been found to have an important function during heart
development. The role of TGFβ isoforms during heart development is not clearly
understood. Not much is known about the TGFβ3 although it is present in the
epicardium along with TGFβ1 and TGFβ2. TGFβ2 deficient mice have defects in
valve development and septation. In addition data suggest that ALK5 play a role in
heart looping (Sanford et al., 1997). TGFβ1, 2 and 3 are reported to be
immunolocalized in all tissues of the heart. TGFβ2 being the most prominent in
cardiomyocytes is also localized at the media and adventitia layer of the blood
vessels and in the outflow track (OFT) of the heart. TGFβ1 is expressed in the
endocardial layer and TGFβ3 is expressed in the cardiac cushions and cardiac
fibroblasts (Molin et al., 2003). TGFβ signaling has been implicated in epithelial to
mesenchymal transition not only of the cardiac cushion but also of epicardial derived
cells but it is not yet clear whether it stimulates or inhibits EMT of epicardial derived
cells . Studies from different laboratories are contradictory. In the chicken embryo
addition of TGFβ2 and TGFβ3 inhibit EMT in epicardial monolayers. This contrasts
with previous reports that showed treatment with TGFβ3 to chicken explanted hearts
induced EMT. Although debatable, most reports suggest TGFβ signaling can induce
EMT (Compton et al., 2006; Dokic and Dettman, 2006; Morabito et al., 2001).

VEGF ligands and receptors are important during coronary vasculogenesis.
Induction of VEGF expression is controled by a FGF9/FGFR1c/FGFR2c pathway

118

that leads to the indirect activation of SHH. SHH expressed in the epicardium
induces expression of VEGF in the myocardium signaling to its receptor Patched1.
Induction of VEGF signaling by FGF is not completely abrogated, therefore, we
hypothesized that other RTKs could be part of the normal VEGF activation and that
these could elicit a compensatory mechanism observed in the Fgfr1/r2Mlc2v-Cre mouse
model. Another possibility is that RTK’s could directly regulate expression of
VEGF, independent of SHH signaling. In this study we explored TGFβ signaling as a
candidate signaling pathway to induce VEGF expression during coronary vascular
formation. TGFβ signaling could be one compensatory pathway by which VEGF
activation is induced along with FGF. Alternatively, TGFβ could directly regulate
expression of VEGF through it downstream effectors Smad2/3.
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Results
In Fgfr1/r2Mlc2v-Cre embryonic hearts, the vascular plexus basal to apical
migration is delayed. This delay is attributed to a decrease in VEGF expression in
knockout hearts. We hypothesize that TGFβ signaling could be increased in
Fgfr1/r2Mlc2v-Cre embryonic hearts as a compensatory mechanism to induced VEGF
expression and in turn vascular tube formation. In order to examine this hypothesis
we performed western blots of control and Fgfr1/r2Mlc2v-Cre hearts to look at the
expression of activated Smad 2/3 the transcription factors downstream of TGFβ
signaling normalized to endogenous Smad2/3 at E12.5 and E13.5 (Figure 1A-1B).
We quantified the amount of protein but we were unable to detect any differences
between controls and Fgfr1/r2Mlc2v-Cre hearts suggesting that TGFβ does not act as a
compensatory mechanism to assure the proper formation of the primitive vascular
plexus (Figure 1C.)
Next we hypothesize that TGFβ signaling could directly regulate the
expression of VEGF by the binding of Smad2/3 to VEGF regulatory sequences. We
observed that various VEGF ligands are expressed in a similar spatio temporal
manner during coronary heart development. vegf-b and vegf-c are expressed in the
same gradient fashion as previously describe for vegf-a. This concerted spatiotemporal expression suggests that all three ligands could be co-regulated during
vasculogenesis. To look at known regulatory motifs that could explain these gene
expression patterns, we used the program Promoter Analysis Pipeline. With this
program you can examine the coincidence of binding sites of known transcription
factors between possible co-regulated genes. We analyzed the promoter regions of
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vegf-a, vegf-b and vegf-c and observed that they shared conserved and non-conserved
Smad2 binding motifs (Figure2A-2C). This finding suggested that TGFβ signaling is
capable of regulating VEGF ligand expression in a coordinated manner.

To test if Smads could control VEGF expression directly by binding to VEGF
ligand regulatory sequences we created a myocardial deletion of Tgfβr2. TGFβR2
binds all three TGFβ ligands and is necessary to phosphorylate the receptor type I
complex. We hypothesize that TGFβ ligands expressed in endocardium, epicardium
and/or myocardium could bind TGFβR2 in cardiac myocytes and elicit the activation
of Smad2/3 in myocardial cells. Smad2/3 in turn could directly bind to VEGF
sequences in cardiac myocytes. Binding of Smad2/3 could induce VEGF expression
in cardiac myocytes and VEGF ligands emanating from cardiac myocytes could
activate VEGF receptors localized at endothelial cells to induce endothelial tube
formation. To test this hypothesis, we stained controls and Tgfβr2Mlc2v-Cre from E12.5
and E13.5 with Pecam, a marker for endothelial cells that marks the primitive
vascular plexus. We observed no change in the density or rate of vascular formation
in Tgfβr2Mlc2v-Cre compared to control hearts (Figure 3).
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Discussion
Our laboratory has demonstrated that FGF signaling promotes proliferation of
the cardiomyoblast cell population and coronary vascular development (Lavine et al.,
2005). FGF9 and FGF16 signal to FGFR1 and FGFR2 in the myocardium to induce
proliferation and simultaneously promoting SHH activity. SHH signaling directly
regulates VEGF and in turn coronary vascular formation (Lavine and Ornitz, 2008).
In the Fgfr1/r2Mlc2v-Cre mouse model, the delay in vascular development is moderate
suggesting that other growth factors might play a role in vasculogenesis. TGFβ has
been proposed to be an angiogenic factor and a regulator of FGF signal in vitro, but
there is a lack of data to link TGFβ to coronary vascular formation (Hildner et al.,
2010).

Here we tried to find evidence that TGFβ could have a role in coronary
vascular formation through interaction with FGF signaling by either a compensatory
mechanism or a synergistic mechanism. It has been reported that FGF and TGFβ
have both opposing and combinatorial effects in different biological processes
(Bosse et al., 2006; Ko et al., 2009; Lee et al., 2010; Ramos et al., 2010). We were
unable to observe a differential expression of TGFβ upon deletion of FGF receptors
in the myocardium, suggesting that TGFβ is unlikely to compensate for the lack of
FGF signaling during midgestation. One possible explanation is that many other
receptor tyrosine kinases are recruited to ensure proper growth and formation of the
coronary vasculature. This could be a mechanism of heart development to protect
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organ survival via a compilation of redundant pathways. Other possible RTK’s
involved in myocardial growth are IGF2, Erb and PDGF signaling.

The observation that TGFβ is unchanged upon FGF signaling ablation does
not eliminate the possibility that TGFβ signaling could control vessel development
directly in cardiac fibroblasts. Although all three VEGF ligands have binding
sequences for Smad in their promoter region we did not observed any defect in the
formation of the vasculature, suggesting that VEGF ligands are able to signal
properly in the absence of TGFβ signaling from the cardiomyocytes. This result
suggests that TGFβ signaling is dispensable in the cardiac myocyte because no other
growth or morphological defects were observed. Consistent with this observation
deletion of Alk5 (a TGFβ type I receptor) in the myocardium results in no phenotype
(Sridurongrit et al., 2008). Alternatively, TGFβ action could be necessary in other
cell type of the heart during coronary vascular formation. TGFβ ligands are
expressed in many other cell types such as the epicardium, endocardium, cushion
mesenchyme, cardiac fibroblast and smooth muscle cells, and endothelial cells.
Elucidating which cell type requires the activation of TGFβ will require conditional
inactivation of these genes. Another possibility is that another TGFβ receptor type II
could be acting redundantly within the cardiac myocyte.

To conclude, we found that FGF signaling does not interact with TGFβ to
contribute to formation of the coronary vasculature and that TGFβ signaling in the
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myocardium is dispensable for coronary vascular development. This conclusion is
consistent with published results were deletion of Alk5 (a receptor type 1) in the
myocardium does not play a major role in the myocardium during development.
Taken together this information supports that TGFβ signaling in the myocardium is
not necessary for heart development (Sridurongrit et al., 2008).
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Materials and Methods

Western blot
Homogenize heart in RIPA buffer with protease inhibitor cocktail. Measure
protein concentration using Bradford test and boil sample for 5min at 95°C. Run gel
using precast biorad gels and Biorad running gel buffer. Transfer 1h and 30min at 8 0
volts at 4°C. Block for 1h with 5% powder milk at 4°C. Primary antibody (Santa
Cruz Biotechnologies, sc-11769) 1h. Incubate in secondary antibody for 1h. Develop
using luminescent reagent. Strip and reprobe.

Promoter analysis pipeline (PAP)
Is a software developed by the Washington University Biomedical
Informatics Core. The software analyzes a set of co-expressed genes (in this case
VEGF ligands co-expressed in the heart) to identify possible transcription factor that
could be orchestrating their co-expression in vivo. The software identifies shared
transcription factor motifs that are found in the promoter region of the genes of
interest. To use this software you create an account in the following website
http://bioinformatics.wustl.edu/webTools/PromoterAnalysis.do;jsessionid=2D5029F
D0BAF20BC7E82F452B8CD97CD
Once created you are able to input the accession numbers of your genes of interest.
The software runs remotely so you do not have to download the program. The results
are displayed with an option to export them to your personal files.
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Whole mount immunohistochemistry of pecam
Tissue is fixed in 4%PFA overnight at 4°C. Tissue is dehydrated in methanol
series and block from endogenous peroxidase using 4 to1 volumes of methanol to
30% hydrogen peroxide for 3h. Tissue is rehydrated in methanol series. Tissue i s
incubated with ProteinaseK 10μg/ml for 30 min at room temperature. Block with 2%
skim milk, 5% serum, 0.1%BSA, 0.1%triton-x for 2h. Primary (Abcam, ab28364)
antibody in blocking overnight. Secondary antibody byotinilated. Develop in DAB.
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Figures and Figure Legends
Figure 1.
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Figure 1.
Western blot for Smad2/3 and pSmad2/3 at embryonic stages E12.5 and
E13.5. (A) Shows the expression of Smad2/3 (top row) and pSmad2/3 (bottom row)
of control and Fgfr1/r2 Wt1-Cre knockout hearts. Expression of Fgfr1/r2 Wt1-Cre is similar
to controls in both the endogenous Smad2/3 and pSmad2/3 at E12.5. (B) Shows the
expression of Smad2/3 (top row) and pSmad2/3 (bottom row) of control and
Fgfr1/r2Wt1-Cre knockout hearts. Expression of Fgfr1/r2Wt1-Cre is similar to controls in
both the endogenous Smad2/3 and pSmad2/3 at E13.5. HepG cells were used as
negative control. Positive control was obtained by inducing HepG cells with TGFβ3
protein to induce Smad phosphorilation. (C) Quantification of optical density for
western blots resulted in no change once normalized to endogenous levels of
Smad2/3. Controls and Fgfr1/r2Wt1-Cre + n=4.
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Figure 2.

133

Figure 2.
Shared promoter sites for Smad3 in vegf-a, vegf-b and vegf-c. (A) Shows
conserved and non conserved Smad3 transcription binding site on (hs) human and
(Mm) mouse for vegf-a. (B) Shows conserved and non conserved Smad3
transcription binding site on (hs) human and (Mm) mouse for vegf-b. (C) Shows
conserved and non conserved Smad3 transcription binding site on (hs) human and
(Mm) mouse for vegf-c
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Figure 3.
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Figure 3.
Whole mount pecam immunohistochemistry. (A-A’) Tgfβf/+, n=3 , E12.5 and
E13.5 respectively . (B-B’) Tgfβf/f (C-C’) E12.5 and E13.5 respectively. n=3
Tgfβr2Mlc2v-Cre n=3 E12.5 and E13.5 respectively. Scale: 500μm
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Appendix B
Inactivation of Fgfr1 and Fgfr2 using the epicardial specific Gata5-Cre does not
affect, epicardial development or coronary vascular formation during midgestation
Mónica Vega Hernández, David M. Ornitz

Abstract
Previously we found that deletion of Fgfr2b in the germline leads to decrease
cardiomyocyte proliferation and as a smaller heart. Germline inactivation causes
deletion of Fgfr2b in all the cells of the mouse embryo, therefore we cannot
distinguish in which cell type is the action of Fgfr2b required. We hypothesized that
Fgfr2b and or Fgfr1b could be functioning in the epicardial layer of the heart. Here
we deleted Fgfr2b and Fgfr1b specifically from the epicardium using Gata5-Cre. We
found that unlike deleting Fgfr1 and Fgfr2 with another epicardial Cre (Wt1-Cre) or
deleting Fgfr2b in the germline deletion of Fgfr2b and Fgfr1b during the spatiotemporal context of Gata5-Cre activation is dispensable for heart development.
Differences in the effect of Fgfr2b-/- and Fgfr1/r2Wt1-Cre in heart development vs
Fgfr1/r2Gata5-Cre could be due to various reasons: for example, target of cell type
within the epicardium, effective cre recombination and temporal expression of the
Cre-line.
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Introduction
The epicardium is the outermost layer of the heart. Epicardial cells travel
from the proepicardium to the posterior base of the heart and migrate and extend
over the heart as a single cell layer. Later they undergo epicardial to mesenchymal
transitions to give rise to vascular smooth muscle cells (vsmc), cardiac fibroblasts
and pericytes (Cai et al., 2008; Dettman et al., 1998; Merki et al., 2005; Mikawa and
Fischman, 1992; Mikawa and Gourdie, 1996; Snider et al., 2009). These cells are
very important to the formation of the adult heart. Vascular smooth muscle cells
become part of the arterial wall and cardiac fibroblasts interact with myocytes to
induce proliferation (Kattan et al., 2004; Lavine et al., 2006; Red-Horse et al., 2010).
Epicardial differentiation is not well understood, it is hypothesized that these cells
express different cell fate markers as early as in the proepicardium. In addition, how
these cells migrate into the myocardium is not very well studied either.
FGF signaling is very important during development. The FGF family is
composed of fifteen canonical ligands and four receptors (Itoh and Ornitz, 2008;
Ornitz and Itoh, 2001; Turner and Grose, 2010). FGFR1, FGFR2 and FGFR3, but not
FGFR4, undergo alternative splicing and give rise to alternative splice variants c and
b. FGFR splice variant b is consistently expressed in epithelial like tissues and FGFR
splice variant c is preferentially expressed in mesenchymal like tissue. The ligands
are classified in subgroups due to their sequence similarity and ligands within a
group activate the same receptor splice variant with similar affinity (Itoh and Ornitz,
2004). FGF signal transduction can proceed through the activation of three main
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pathways: Ras/MAPK pathway, phospholipase Cγ (PLCγ)/Ca 2+ pathway, and the PI3
kinase/Akt pathway (Eswarakumar et al., 2005; Lemmon and Schlessinger, 2010).
FGF signaling has been shown to be important during heart development. FGF9
emanating from the epicardium signals to receptors FGFR1c and FGFR2c in the
myocardium to induce cardiomyocyte proliferation (Lavine et al., 2005). In addition
FGFR2b, which is tought to be expressed in the epithelial cell types of the heart, is
also important for the control of heart size. The main epithelial cell types and
epithelial-like cell types of the heart are endothelial cells, endocardial cells and
epicardial cells (Marguerie et al., 2006). We have deleted FGFR1 and FGFR2 using
two endothelial specific Cre alleles (Tie2-Cre and Flk1-Cre) and found that both
animal models to undergo normal heart development. Hence, we hypothesized that
FGFR2b could function in epicardial cells. To test this hypothesis we used Cre-Loxp
recombination to inactivate Fgfr2b in the epicardium using an epicardial specific Cre
(Gata5-Cre) that we refer to here as Fgfr1/r2Gata5-Cre. We found that Fgfr1/r2Gata5-Cre
hearts do not develop a smaller heart, in addition we found that the coronary
vasculature in these hearts is normal. This suggests that FGFR1b and FGR2b in the
epicardium do not exert a function during the spatial and temporal domain of Gata5
expression. Alternatively, recombination by Gata5-Cre could be innefficient or
restricted to a non-fibroblast lineage.
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Results
To determine if Gata5-Cre would induce recombination in the epicardial
layer, we crossed Gata5-Cre mice with the Rosa26 reporter mice (hereafter refer as
Rosa26;Gata5-Cre). We then examined if recombination led to expression of βgalactosidase in the epicardium (Figure 1). We observed that expression of βgalactosidase was present in Rosa26;Gata5-Cre but not in control littermates lacking
either or both: Gata5-Cre and or Rosa26. The expression of β-galactosidase in the
epicardium suggested that Gata5-Cre is able to induce recombination in epicardial
cells.
We then created the Fgfr1/r2Gata5-Cre mice and looked at the general histology
by H&E staining (Figure 2). The H&E showed that at E13.5 Fgfr1/r2Gata5-Cre
embryonic hearts seemed to have less subepicardial space but the thickness of the
compact myocardium was comparable to control littermates. Decrease subepicardial
mesenchyme could result in defects in epicardial EMT, migration and differentiation.
Disruption of these processes can lead to defects in coronary vascular formation
because epicardial derived cells contribute to the media layer of coronary arteries.
We hypothesize that deletion of Fgfr1 and Fgfr2 with Gata5-Cre could lead to
improper formation of the coronary vasculature. We examined the endothelial
vascular plexus of controls and Fgfr1/r2Gata5-Cre hearts and found that coronary artery
formation proceeds normal at E13.5 (Figure 3). We looked at the formation of
subepicardial vessels and intramyocardial vessels and found that both are present in
controls and Fgfr1/r2Gata5-Cre hearts (Figure 3A’-3B’). We next followed the growth
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of these heart at later stages and found that both, their size and coronary vessel
development is normal (Figure 3C-3D).
We measured the relative area of controls and Fgfr1/r2Gata5-Cre at E13.5 and
E17.5 and found no significant difference between them (Figure 3E). We next
wanted to see if the apparent decrease in subepicardial mesenchyme, observed in
Fgfr1/r2Gata5-Cre hearts would lead to defects in EMT. We looked at two main EMT
markers, cytokeratin and vimentin (Figure 4). When cells are undergoing EMT they
shift their cytoskeleton from epithelial-like (cytokeratin) to mesenchymal –like
(vimentin). We observed no difference between controls and Fgfr1/r2 Gata5-Cre hearts
in their expression of cytokeratin in the epicardial layer or vimentin within the
myocardial area. We measured the relative pixel intensity (mgv) of the cytokeratin
expression in the epicardium and failed to find any significant change between
littermate controls and Fgfr1/r2Gata5-Crehearts. Next, we checked Wt1 expression
because this gene has been shown to induce epicardial to mesenchymal transition
(Figure 5). We measured the total number of Wt1 + cells within the epicardium, sub
epicardium and myocardium and found no difference in the total number of Wt1 +
cells when compared to controls and Fgfr1/r2Gata5-Cre+ embryonic hearts.
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Discussion
We expected that ablation of Fgfr1 and Fgfr2 in the epicardium with Gata5-Cre
would lead to a smaller heart similar to Fgfr2b-/- phenotype, but failed to detect any
differences between controls and Fgfr1/r2Gata5-Cre hearts. This result is surprising
because it differs from the results we observed in chapter two of this thesis using the
Wt1-Cre allele. Using Wt-1Cre, we observed a very similar phenotype to the Fgfr2b/-

mouse. We propose that these differences could be due to the following reasons:
1. The time of expression of Gata5-Cre. The germline knockout of Fgfr2b is deleted
throughout development, therefore, the function of FGFR2 is abrogated at all time
points in development. On the other hand Gata5-Cre starts to be expressed at
E9.25 in proepicardial cells and continues to be expressed in the epicardial cell.
Alternatively, Wt1-Cre expression starts in the proepicardium at E9.5 and
continues to be expressed in the epicardium all throughout development, similar
to Gata5-Cre. These differences in timing of ablation could lead to different
phenotypic results.

2. The cell type that expresses Gata5-Cre. The germline knockout targets every
single cell in the mouse embryo but Gata5-Cre only targets the proepicardial and
epicardial cells but not the epicardial derived cells. In contrast Wt1-Cre continues
its expression in epicardial derived cells making it not only an epicardial deletion
but also an epicardial derived cell deletion of FGFR1 and FGFR2. These
differences could account for the discrepancy in the phenotypes.
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3. The type of Cre. Gata5-Cre is a transgenic Cre insertion but Wt1-Cre is a knockin of Wt1 sequences driving cre recombinase cDNA inserted at the Wt1 gene
locus. This insertion results in the expression of just on normal allele of Wt1. It is
possible that haploinsufficiency of Wt1 could create a more sensitive genetic
background and result in the different phenotypes we described here and in
chapter two. However, alone, Wt1-Cre does not affect EPDC migration into the
myocardium.

4. Background of mouse strains. Although both Gata5-Cre and Wt1-Cre have been
mated into mix backgrounds there still a possibility that the genetic makeup of the
lines is different and susceptibility mutations could be generating the contrasting
phenotypes.

5. The phenotype in Gata5-Cre might not be as severe. The phenotype could still be
present in Fgfr1/r2Gata5-Cre hearts but differences like the ones mentioned: mouse
strain, timing and temporal expression could be responsible for a less severe
phenotype that we don’t have the sensitivity to detect.

6. In addition, the effectiveness of Cre recombination could be compromised in
Gata5-Cre.
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Materials and Methods
LacZ staining
Staining for β-galactosidase was performed as described (Soriano, 1999).

Histology
Paraffin sections (5µm) were stained with hematoxilin and eosin (H&E) for
general visualization. Myocardial area was calculated with the contouring tool using
Canvas X software. Area of the heart was defined as the measure of total muscle
including both chambers in one whole mount picture. Atrial area was not included. In
Fgfr1 Wt1-Cre, Fgfr2 Wt1-Cre and Fgfr1/2 Wt1Cre. Statistical significance was determined
using the student’s t-test, with n representing number of embryonic hearts examined.

Whole mount immunohistochemistry of pecam
Tissue is fixed in 4%PFA overnight at 4°C. Tissue is dehydrated in methanol series
and block from endogenous peroxidase using 4 to1 volumes of methanol to 30%
hydrogen peroxide for 3h. Tissue is rehydrated in methanol series. Tissue is
incubated with ProteinaseK 10μg/ml for 30 min at room temperature. Block with 2%
skim milk, 5% serum, 0.1%BSA, 0.1%triton-x for 2h. Primary (Abcam, ab28364)
antibody in blocking overnight. Secondary antibody byotinilated. Develop in DAB.
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Immunofluorescence
For immunofluorescence, paraffin sections (5μm) were dewaxed, rehydrated,
incubated in methanol/hydrogen peroxide, antigen unmasked, and blocked in 10%
goat serum. Antigen unmasking was performed by incubating sections in 1% trypsin
for 5 min at room temperature or by pressure cooking in citrate buffer for 15 min.
Primary antibodies used were cytokeratin (Dako, M3515),vimentin (mouse IgM,
abcam, ab20346), Wt-1 (mouse IgG1κ, Dakocytomation, M3561), Secondary
antibodies were incubated for 1hr and visualized with a Zeiss confocal microscope or
Zeiss apotome microscope.
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Figure and Figure Legends
Figure1.
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Figure 1.
β-galactosidase staining of control hearts at E13.5. (A-B) Whole mount βgalactosidase staining for (A) control (Rosa26) and (B) Rosa26;Gata5-Cre at E13.5.
(A’) Coronal cross section of control without Cre and (B’) coronal section of
Rosa26;Gata5-Cre. (A’’-B’’) Magnified inset from black squares in (A’-B’). Scale
bars: (A-B) and (A’-B’) 500μm, (A’’-B’’) 10μm.
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Figure 2.
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Figure 2.
H&E staining. (A) Coronal cross section of control heart stained with
hematoxylin and eosin at E13.5. (B) Coronal cross section of Fgfr1/r2Gata5Ccre heart
stained with hematoxylin and eosin at E13.5. Scale bar: 20μm.
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Figure 3.
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Figure 3.
Pecam immunostaining. (A-B) Whole mount Pecam staining of control (A)
and Fgfr1/r2Gata5-Cre (B) at E13.5. (A’-B’) Cross-section of whole mount Pecam
stained hearts at E13.5 control. (C-D) Pecam staining of control (C) and
Fgfr1/r2Gata5-Cre (D) at E17.5. Main coronary vessels are highlighter in gray in (CD). (E) Quantification of the area of the heart at E13.5 (controls, n=5, Fgfr1/r2Gata5Cre

, n=4) and E17.5 (controls, n=3, Fgfr1/r2Gata5-Cre, n=3). Scale bar (A-B) and (C-D)

500μm, (A’-B’) 20 μm.
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Figure 4.
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Figure 4.
Immunofluorescence of cytokeratine and vimentin. (A-B) Cytokeratin (red)
staining in controls (A) and Fgfr1/r2Gata5-Cre (B). (A’-B’’) Vimentin (green) staining
in controls (A’) and Fgfr1/r2Gata5-Cre (B’). (A’’-B’’) Merge with DAPI (blue) staining
in controls (A’’) and Fgfr1/r2Gata5-Cre (B’’). (C) Quantification of cytokeratin average
fluorescence controls, n=9, Fgfr1/r2Gata5-Cre, n=6. Dapi (blue). Scale bar: 20μm.
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Figure 5.
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Figure 5.
Wt1 immunofluorescence. (A-B) Wt1 (red) immunostaining for control (A,
n=9) and Fgfr1/r2Gata5-Cre (B, n=5). White dashed line delimits the boundary between
epicardium and myocardium. (C) Quantification of total Wt1 in epicardium (epi),
subepicardium (subepi), and myocardium (myo) of control and Fgfr1/r2Gata5-Cre at
E13.5. DAPI (blue). Scale bar: (A-B) 20μm.
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